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ABSTRACT 
Epstein-Barr virus (EBV) is a ubiquitous tumour-causing virus which infects 
more than 90% of world population asymptomatically. It is closely associated with 
nasopharyngeal carcinoma (NPC). LMP-1, -2A and -2B are three latent membrane 
proteins (LMPs) encoded by EBV which are frequently detected in NPC tumour. Recent 
studies suggest that these three proteins co-operate in the tumorigenesis of NPC but the 
mechanism is not clear. In this study, LMPs were cloned into pcDNA3.1 and transfected 
into HEK293T cell line to reveal their oncogenic mechanism via investigation on their 
involvement in the regulation of cell cycle and genes that are involved. The 
transcription of cell cycle arrest genes were examined via semi-quantitative reverse 
transcription-PCR and real time PCR. Cell cycle progression was examined via flow 
cytometry. LMPs were successfully cloned in pcDNA3.1 and expressed in HEK293T in 
single and co-expression manner. 14-3-3σ and Reprimo were upregulated in all LMP-1 
expressing cells. Moreover, cell cycle arrest at G2/M progression was detected in all 
LMP-1 expressing cells. Therefore, we conclude that LMP-1 may induce cell cycle 
arrest at G2/M progression via upregulation of 14-3-3σ and Reprimo. 
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ABSTRAK 
Epstein-Barr virus (EBV) adalah virus penyebab ketumbuhan yang biasa 
menjangkiti lebih daripada 90% penduduk dunia. Ia berkait rapat dengan karsinoma 
nasofarinks (NPC). LMP-1-2A dan 2B adalah tiga membran protein terpendam (LMPs) 
yang dikodkan oleh EBV yang kerap dikesan di dalam  ketumbuhan NPC. Kajian baru-
baru ini menunjukkan bahawa ketiga-tiga protein ini bekerjasama dalam tumorigenesasi 
NPC, namun mekanisme ini masih tidak jelas. Dalam kajian ini, LMPs diklonkan ke 
dalam pcDNA3.1 dan ditransfeksikan ke dalam titisan sel HEK293T untuk 
mendedahkan mekanisme onkogenik mereka melalui siasatan ke atas penglibatan 
mereka dalam peraturan kitaran sel dan gen yang terlibat. Transkripsi gen yang terlibat 
dalam penahanan kitaran sel telah diperiksa melalui PCR transkripsi berbalik semi-
kuantitatif dan PCR masa nyata. Perkembangan kitaran sel diperiksa melalui sitometri 
aliran. LMPs telah berjaya diklon ke dalam pcDNA3.1 dan diekspresikan dalam 
HEK293T sel secara tunggal dan ekspresi bersama. Ekspresi 14-3-3σ dan Reprimo telah 
meningkat dalam semua sel yang mengekspresikan LMP-1. Selain itu, penahanan 
kitaran sel pada perkembangan G2/M dikesan di dalam semua sel yang 
mengekspresikan LMP-1. Oleh itu, kami menyimpulkan bahawa LMP-1 boleh 
mendorong penahanan kitaran sel pada fasa G2/M dengan meningkatkan ekspresi 14-3-
3σ dan Reprimo. 
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1.1 Discovery of Epstein-Barr Virus (EBV) 
In 1957, Denis Burkitt, a surgeon who is working in Kampala, Africa, was 
called for a consultation on a child with tumors on both sides of the upper and lower 
jaws. This observation leads him to the first discovery of ―African Lymphoma‖ and now 
known as Burkitt’s lymphoma (BL). In order to determine the cause of this malignancy, 
Burkitt and his colleagues collected data from all over Africa. Finally, Burkitt suggested 
that a viral infection was involved in the aetiology of this tumor (Burkitt and O’Conor, 
1961; Burkitt, 1972; Tselis, 2006). 
A meeting with Dr. Anthony Epstein in 1961, Burkitt agreed to send the biopsy 
samples from BL patients to UK for further investigation. When Epstein and his 
colleagues at the Middlesex Hospital, London, studied about the BL cell lines under 
electron microscopes, the virus particles were observed with similarity to morphology 
of herpex simplex virus (Epstein et al., 1965). This new identified virus was then 
grouped as a member of herpesviridae family and named Epstein - Barr virus (EBV) 
after discovery by Michael Epstein and Yvonne Barr, who together with Bert Achong in 
year 1964, which turns out to be the first candidate of human tumor virus (Tselis, 2006). 
Several human malignancies are now proved to be related to the oncogenic 
properties of EBV, including nasopharyngeal carcinoma (NPC) in southern China, 
including Hong Kong, Hodgkin’s Lymphoma (HL), as well as Burkitt’s Lymphoma 
(BL) in Africa and Papua New Guinea (Raab-Traud, 1996; Crawford, 2001; Tsuchiya, 
2002; Rickinson and Kieff, 2007). EBV associated malignancies were summarized in 
table 1.1. EBV is a ubiquitous tumor causing virus, infected more than 90% of the adult 
in world population and achieves life-long infection in B lymphocytes asymptotically 
(Crawford, 2001). 
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Table 1.1: EBV-associated malignancies (Crawford, 2001). 
 
Tumor Cell of origin Approximate EBV 
association 
Cofactors/risk 
factors 
Burkitt’s lymphoma Centroblast African 96%  
Sporadic 10-70% 
AIDS 30-40% 
Malaria, c-myc 
deregulation, HIV 
B- 
Lymphoproliferative 
disease 
B Lymphoblast 90% Immunosuppression, 
HIV 
Hodgkin’s 
Lymphoma 
Centrocyte 40-80% Infectious 
Mononucleosis (IM) 
T-cell lymphoma T lymphocyte 10% Chronic IM, 
immunosuppression 
Nasopharyngeal 
Carcinoma 
Squamous epithelial 
cell 
100% Genetic & dietary 
factors 
Gastric carcinoma Epithelial cell 10% Unknown 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1          Introduction 
3 
 
1.2 EBV virus: Structure and genome map  
EBV is a double stranded DNA virus which is belonged to the 
gammaherpesvirus family (Raab-Traub, 2002) that encodes nearly 100 viral proteins 
which play the important role in the lytic production of EBV virions and suppression of 
host immune system (Hiraki et al., 2001). Like other gammaherpesviruses, its linear, 
double stranded DNA which is wrapped with an inner core followed by a capsid which 
consists of 162 capsomeres with about 100 nm in diameter; a tegument which surround 
the nucleocapsid; and an outer envelope with external glycoprotein spikes for binding 
the virion the cell surface receptor (Figure 1.1) (Epstein et al., 1965; Kieff and 
Rickinson, 2007). The major EBV capsid is formed by combination of proteins with 
155 kDa major capsid protein, 30 kDa minor capsid protein, 18 kDa small capsid 
protein, 40 kDa minor capsid protein binding protein, and 68 kDa portal protein, all in 
the expected ratios, based on 12 portal molecules per virion (Kieff and Rickinson, 2007). 
The EBV tegument is a combination of the 350 kDa large tegument protein (BPLF1), 
140 kDa large tegument protein binding protein (BOLF1), 15 kDa myristylated protein 
(BBLF1), 32 kDa myristylated protein binding protein (BGLF2), 58 kDa capsid 
associated protein (BVRF1), 58 kDa packaging protein (BGLF1), 27 kDa palmitylated 
protein (BSRF1), and 47 kDa TS kinase (BGLF4), which are similar to other 
Herpesvirus teguments. In addition, EBV has a 140 kDa major tegument protein 
(BNRF1), 19 kDa BLRF2, 72 kDa BRRF2, 54 kDa BDLF2, 42 kDa BKRF4, which are 
also similar to other gammaherpesvirus. Besides, cellular proteins such as actin, HSP70, 
Cofilin, β-tubulin, enolase, and Hsp90 also can be found in EBV tegument, which are 
probably related to cytoplasmic re-envelopment. EBV has a range of envelope 
glycoproteins which are known as EBV gp350 (BLLF1), gH (BXLF2), gB-N, gB-C, 
and full-length gB (BALF4), gp42 (BZLF2), gM (BBRF3), gp78 (BILF2), gN (BLRF1), 
gp150 (BDLF3), and gL (BKRF2), respectively. However, the major envelope protein 
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gp350/220, which is exclusive to EBV and also played an important role in membrane 
adhesion, thus it allows the virus enter to host cells (Hutt-Fletcher, 2007; Maruo et al., 
2001). 
 
  Spikes 
  
   
          Envelope 
           
 
          Tegument 
 
 
          DNA code 
 
 
          Capsid 
 
 
 
Figure 1.1: Schematic diagram of EBV. The EBV particle consists of four basic 
components: Inner DNA core, a capsid, an amorphous tegument, and an outer envelope 
with external glycoproteins spikes. 
 
In 1984, B95.8 prototype laboratory strain of EBV is fully sequenced using 
BamHI fragment library (Baer et al., 1984). Thus, sequences like genes, open reading 
frames (ORFs) and promoters is referred to the corresponding fragment. For example, 
an envelope glycoprotein gp110 which is named as BALF4 due to its ORF (F) on the 
BamHI A (BA) fragment, and its position is fourth leftward (Figure 1.2). 
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Figure 1.2: BamHI restriction endonuclease map of prototype B95.8 EBV genome.  
The fragments are named according to their size from the largest to the smallest in 
alphabetical order. TRs are shown in grey color at both termini of the genome (Young 
and Rickinson, 2004). 
 EBV genome consists of approximately 184 kbp DNA in length with 60  percent 
of guanine or cytosine; 0.5 kbp tandem direct repeats (TR) of the same sequence at both 
termini; six to 12 tandem reiterations of 3 kbp internal repeats (IR1) and two short and 
long unique sequence domains (US and UL). After infection, the EBV achieves latent 
phase in proliferative cells by joining its TRs to produce a circular DNA (episome) 
(Figure 1.3). Each EBV episome in progeny infected cell generally tends to have a same 
number of TRs as parental genome. During viral DNA replication, the unique cleavage 
and joining events of the single viral genome, different numbers of TRs are introduced 
to the termini of the viral genome. Therefore, the numbers of TRs in latently infected 
cells are useful to determine the common progenitor (Kieff and Rickinson, 2007).   
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Figure 1.3: EBV episome. The origin of the plasmid replication is oriP which is shown 
in orange. The latent genes expressions are shown in black arrow. The gene 
transcription initiation is started at promoter C (Cp) or Wp and Qp. (Young and 
Rickinson, 2004). 
 
Two types of EBV exist in most populations which are designated as type 1 
EBV and type 2 EBV. Type 1 is the most common in most population but type 2 is 
nearly as common as type 1 in equatorial Africa and New Guinea (Kieff and Rickinson, 
2007). The differences between these two types are in the gene encoded for EBV 
nuclear proteins (Dambaugh et al., 1984; Kieff and Rickinson, 2007; Sample et al., 
1986). 
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1.3 Life cycle of EBV 
EBV infects almost all individuals in human population in the world and 
achieves life-long infection in human but the biology of EBV infection in vivo (Figure 
1.4) is still ambiguous. Primary infection usually occurs during childhood and is 
asymtopmatic, but in some development countries which may delay until adulthood or 
adolescence and resulting in appearance of clinical syndrome of infectious 
mononucleosis (IM) (Crawford et al., 2006; Young and Rickinson, 2004).  
EBV is orally transmitted and its primary site of infection is generally at 
oropharyngeal site. High titers of infectious virus are found in the acute IM patients. 
Thus, oropharyngeal site is believed to be the location for viral replication because this 
region can ensure the productions of new virions in oropharyngeal secretions and are 
easier to transfer to the new susceptible hosts during persistent lytic infection (Young 
and Rickinson, 2004).  
 After infection at oropharyngeal site (possibly in the mucosal epithelium), EBV 
establishes lytic replication and spread out the viral particles throughout the lymphoid 
tissues. EBV begins with infect B lymphocytes through binding of gp350 to the CD21 
receptor on the cell surface and through the binding of gp42 to human leukocyte antigen 
(HLA) as a second co-receptor. Next, EBV establishes a latent growth-transforming 
infection (latency III) and majority of these proliferating cells will be removed by the 
emerging latent-antigen-specific primary-T-cell response but some of the cells escape 
and achieve latency 0 by downregulating viral antigen expression. Thus, it establishes a 
stable reservoir of resting viral-genome positive memory B cells. For EBV infected 
naïve B cells, EBV transforms naïve B cells into memory by mimicking the 
physiological process of antigen-driven memory B cell development in lymphoid tissues 
during transit through the germinal center which involving somatic immunoglobulin-
gene hypermutation process. However, the process still waiting to be proven due to the 
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discovery of EBV-infected B cells in tonsils from patients with IM which localize to 
extrafollicular area but not germinal centres (Young and Rickinson, 2004). 
 For the persistent infection, the EBV infected cell is recruited into germinal-
centre, which follows by different latency activation. However, some of the infected B-
cell might reenter the reservoir as memory cells and the remaining cells will 
differentiate into plasma-cell which move to mucosal site in the oropharynx and activate 
the lytic cycle. The virions produced might initiate lytic replication in permissive 
epithelial cells and allow the production of infectious virus in oropharynx. Some virions 
also might reinfect the naïve and memory B cell to achieve growth-transforming latency 
III infection and replenish the reservoir but are more likely to be removed by the well 
established memory T-cell response (Young and Rickinson, 2004).  
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Figure 1.4: Schematic in vivo infection of EBV. Diagram showed the (a) primary 
infection and the (b) persistent infection of EBV (Young and Rickinson, 2004). 
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1.4 Stages of EBV infection 
1.4.1 Lytic infection 
The in vitro infection of human resting B cells with EBV, which establishes a 
Lymphoblastoid cell lines (LCL) and which is widely use as a tool for examining the 
EBV infection and lytic replication. Lytic infection is usually studied by inducer such as 
TGF-beta, phorbol esters [12-O-tetradecanoylphorbol-13-acetate (TPA)], butyric acid 
etc (Kieff and Rickinson, 2007). During the lytic replication, EBV expresses about 90 
proteins which are classified as immediate-early, early and late proteins. Immediate-
early proteins are expressed just after infection in the presence of protein synthesis 
inhibitors and early proteins are expressed in the presence of viral DNA synthesis 
inhibitors, but for late proteins which are not transcribed in the presence of these 
inhibitors.  Immediate-early proteins play a role in regulating the gene expression in the 
virus; early proteins are important for virus DNA replication, and late proteins are 
structural proteins which compose the EBV virion (Cohen, 2006). 
 
1.4.2 Latent infection 
There are nearly 100 EBV genes in EBV genome, however there are only a few 
genes expressed in latent infection. The expression of only a few genes in EBV latent 
infected cells is mainly to reduce recognition of viral antigen by cytotoxic T-cells 
(Hiraki et al., 2001). There is only a limited set of latent genes including six EBV 
nuclear antigens (EBNA1,-2,-3A,-3B,-3C and LP); three latent membrane proteins 
(LMP1, LMP2A and LMP2B); two non coding EBV-encoded RNA (EBER1 and 
EBER2); and transcripts from the BamHI A region of EBV genome (Hiraki et al., 2001; 
Cohen, 2006; Kieff and Rickinson, 2007). Latent genes have been shown to have 
significant transformation ability in EBV infected B-cells (Cohen, 2006).   
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1.4.2.1 Pattern of EBV latency 
In different EBV-related pathological situations, different set of EBV genes are 
expressed and represent as different latency. There are four types of latency in EBV 
latent infection (Cohen, 2006; Hiraki et al., 2001; Kieff and Rickinson, 2007; Rowe et 
al., 1992) (Table 1.2). 
 
Table 1.2: Patterns of EBV latency in different diseases. 
Latency EBNA1 EBNA2 EBNA3 LMP1 LMP2 EBER Diseases 
I + - - - - + Burkitt’s Lymphoma (BL) 
 
II + - - + + + Hodgkin’s Disease, Peripheral T 
cell Lymphoma & Nasopharyngeal 
Carcinoma (NPC) 
 
III + + + + + + Lymphoproliferative disease, X-
linked lymphoproliferative Disease 
& Infectious mononucleosis (IM) 
 
Other ± - - - + + Healthy carrier 
 
Latency I: 
In type I latency, only restricted genes such as EBNA-1 and EBER are expressed. This pattern of latency 
can be found in tissue of Burkitt’s lymphoma and gastric carcinoma. 
Latency II: 
In type II latency, EBNA-1, LMP-1, LMP-2 and EBER are expressed. This type of latency is seen in 
tissues from Hodgkin’s disease, Peripheral T cell Lymphoma and Nasopharyngeal Carcinoma (NPC) 
patients. 
Latency III: 
In type III latency, all EBV latent genes are expressed as well as EBERs and some BamHI A RNAs. 
Latency III is associated with Lymphoproliferative disease, X-linked lymphoproliferative Disease and 
Infectious mononucleosis (IM). 
Other: 
In healthy carrier, most of the time LMP-2 and EBERs are expressed but only sometime EBNA is 
expressed. 
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1.5 LMP-1 
1.5.1 LMP-1 structure 
The Epstein–Barr virus latent membrane protein 1 (LMP-1) is an integral 
membrane protein with a molecular weight of approximately 63 kDa which consists of 
three major segment or domains. It begins with a 24 amino acids N-terminal 
cytoplasmic domain which is responsible for maintaining the orientation of the LMP-1 
in the cells (Coffin et al., 2001). Next, it follows by a six transmembrane hydrophobic 
domains with 161 amino acids which responsible in the oligomerization of LMP-1 
molecules (Gires et al., 1997) and activation of the small GTPase Cdc42 which initiates 
the cytoskeletal reorganization (Puls et al., 1999). The last segment is a long 
cytoplasmic C-terminal with 200 amino acids which is rich in acidic residues (Kieff and 
Rickinson, 2007); it can be subdivided into three essential C-terminal activation regions 
(CTARs) 1-3 (Li and Chang, 2003). Hereby, the schematic structure of LMP-1 and its 
functional domains; as well as their associated proteins are presented in figure 1.5. Each 
segments of the LMP-1 have its own specific functions and all three domains of the 
LMP-1 are required for transformation of Rat-1 fibroblasts (Moorthy and Thorley-
lawson, 1993). 
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Figure 1.5: Schematic structure of LMP-1 and its functional domains; as well as 
their associated proteins (Li and Chang, 2003). 
 
1.5.2 Oncogenic roles of LMP-1  
LMP-1 is a well known oncoprotein that commonly causes tumorigenesis by 
activating multiple signaling pathways in a ligand independent manner. The short N-
terminus domain of LMP-1 involves in rapid turnover and localization of the protein 
(Aviel et al., 2000; Coffin et al., 2001). The first 12 a.a. of LMP-1 funtions as a 
ubiquitin binding site (Aviel et al., 2000).  
Furthermore, there are leucine-heptad-like motifs (LLXXLLX) located within 
the first and sixth transmembrane domains (figure 1.5), involved in self-association and 
protein-protein interaction (Kaykas et al., 2002).  Besides, the transmembrane domains 
are also responsible for the oligomerization of LMP-1 molecules (Gires et al., 1997) and 
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activation of the small GTPase Cdc42 which initiates the cytoskeletal reorganization 
(Puls et al., 1999). 
LMP-1 expression in nude mice results in the B-cell lymphoma (Kulwichit et al., 
1998). LMP-1 induces a signaling response in cells that mimics a constitutively active 
form of the B-cell-surface molecule CD40 (Uchida et al., 1999). Besides, LMP-1 
protein also has some functional similarity with some other tumour necrosis factor 
receptor (TNFR) family member like TNFR1 (Mosialos et al., 1995). LMP-1 acts as a 
constitutively activated form of TNFR in a ligand independent manner (Gires et al., 
1997; Kilger et al., 1998). Three functional domains at the C-terminus of LMP-1 that 
trigger the signaling pathway are named transformation effector site (TES) or C-
terminal activator region (CTAR).  LMP-1 interacts with many proteins that also 
interact with TNFR family members, such as TNFR-associated proteins (TRAFs) bind 
to CTAR1 (Devergne et al., 1996), the TNFR-associated death domain protein 
(TRADD) (Izumi and Kieff, 1997) and the receptor interacting-protein (RIP) bind to 
CTAR2 (Izumi et al., 1999) to activate TNFR-associated pathway. 
LMP1 activates NFκB pathway through its CTAR1 or CTAR2. CTAR1 interacts 
with TRAF1, TRAF2, TRAF3 and TRAF5 to activate NFκB pathway (Devergne et al., 
1996; Kieff and Rickinson, 2007). There is a similarity in protein sequences among the 
CTAR1 and the sites in CD40 and CD30 that are essential for NFκB pathway activation 
(Devergne et al., 1996; Miller et al., 1998). Consequently, mimicry of LMP-1 to the 
constitutively activated TNFR can have a similar effect as CD40 on transformation of 
B-lymphocyte and gene activation (Devergne et al., 1996).    
 
 
LMP-l C-terminus contains a proline rich region within 33-bp repeat in between 
CTAR1 and CTAR2 which mediates activation of JAK3. Janus kinase (JAK) mediated 
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activation of signal transducer activators of transcription (STAT) involves in diverse 
cellular processes such as proliferation, apoptosis and cell marker expression. Currently, 
this proline rich region has been named as CTAR3. LMP-1 activates PI3K/Akt with its 
CTAR1 region which is important to promote cell survival and induce actin filament 
remodeling (Dawson et al., 2003).  
LMP-1 also activates mitogen-activated protein kinase (MAPK) pathway such 
as extracellular-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK)/ Stress-
activated protein kinase (SAPK). MAPK plays an important role in coordinating cellular 
activities from gene expression, mitosis, and metabolism to survival, apoptosis and 
differentiation (Roux et al., 2004).  
 ERK-MAPK is activated directly via CTAR1 of LMP-1 and which is important 
in LMP1-induced transformation of Rat-1 fibroblasts (Mainou et al., 2007). Indeed, a 
recent study has identified LMP-1 induced cell motility via ERK-MAPK activation, as 
LMP-1 expressing cells exhibit high rate of haplotactic migration compared to non-
LMP1 expressing cells (Dawson et al., 2008). LMP-1 activated ERK-MAPK contribute 
to the oncogenicity through its ability to promote cell migration and invasive properties.  
 In addition, recent study has demonstrated that LMP-1 activated p38/MAPK acts 
as an autoregulatory loop in LMP-1 upregulation which may be important for LMP-1 
induced cell survival (Johansson et al., 2010). 
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1.5.3 Paradox effects of LMP-1  
 LMP-1 is a well-known classical oncoprotein and is proved to transform rodent 
fibroblast and promote tumorigenesis (Wang et al., 1985). On the contrary, studies on 
LMP-1 suggest that overexpression of LMP-1 exhibits toxicity to the cells 
(Hammerschmidt et al., 1989). According to Le Clorennec et al. (2008), LMP-1 induces 
type II ligand independent autoactivation of CD95/Fas mediated Caspase-8 dependent 
apoptosis. This is thought to cause the cytotoxicity effect of LMP-1. On the other hand, 
LMP-1 may interrupt cell proliferation when introduced into B cell lines. 
Overexpression of LMP-1 impairs the in vitro growth, clonability and tumerigenicity in 
B cell lines (Torsteinsdóttir et al., 1989; Cuomo et al., 1992).  According to Floettmann 
et al. (1996), induction of LMP-1 expression completely inhibits cell proliferation for 4-
5 days by the induction of G2 or M phase cell cycle arrest. This phenomenon of cell stop 
growing is also known as cytostasis. The cells that stop growing usually will be 
followed by either cytotoxicity and cell killing or escape from the stasis and 
repopulation (Rixe and Fojo, 2007). However, how LMP-1 causes cytostasis and arrests 
cells at the G2/M phase are poorly understood. Previous studies show that mRNA and 
protein of p53 are overexpressed in NPC and the consequences of this accumulation 
may be related to EBV infection (Deng et al., 2003; Gulley et al., 1998; Murono et al., 
1999). A recent study showed that LMP-1 induced cell cycle arrest in HNE1 cells which 
are NPC derived cell line through activation of NFκB (Deng et al., 2003). However, the 
exact mechanism of LMP-1 induced cell cycle arrest remains unclear.  
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1.6 LMP-2 
1.6.1 LMP-2 structure 
Latent membrane protein 2 can be divided into 2 subtypes, LMP-2A and LMP-
2B or TP-1 and TP-2 (Laux et al., 1989). The structures of these two proteins are 
similar; both have 12 transmembrane domains and a 27-amino-acid cytoplasmic 
carboxyl terminus (Young and Rickinson, 2004). LMP-2A and LMP-2B are transcribed 
independently by 2 different promoter sequences which are separated by 3kb across the 
fused terminal repeat of EBV genome (Sample et al., 1989). The mRNA transcripts of 
LMP-2A and LMP-2B are 2.3kb and 2.0kb respectively. LMP-2B shares the same 
bidirectional promoter with LMP-1 (Laux et al., 1989). The sizes of the proteins are 
predicted to be 50 kDa for LMP-2A and 40 kDa for LMP-2B (Sample et al., 1989). 
These 2 proteins share 8 common 3’exons, but both have a unique 5’ exon. The eight 
common exons encode 12 transmembrane spanning domains and the C-terminal of 
LMP-2A and LMP-2B.  
The unique LMP-2A N-terminal consists of 119 amino acids hydrophilic 
cytoplasmic domains which mainly responsible for LMP-2A functions (Sample et al., 
1989). N-terminal of LMP-2A contains an immunoreceptor tyrosine-based activation 
motif (ITAM) which consists of paired tyrosine and leucine residues and modulates 
signal transduction of the BCR and the T-cell receptor (TCR) (Fruehling and 
Longnecker, 1997). LMP-2A alters normal BCR signal transduction in B cells through 
reducing levels of Lyn and blocking of tyrosine phosphorylation as well as calcium 
mobilization following BCR cross-linking (Rovedo and Longnecker, 2007). This 
association accounts for the ability of the LMP2A ITAM to block BCR signal 
transduction, thereby preventing the induction of lytic EBV replication in B cells 
(Miller et al., 1995). LMP-2 C-terminal is a cysteine rich sites and its 12 transmembrane 
domains contain clustering signal which are believed to be essential for LMP-2 
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functions (Katzman and Longnecker, 2004; Matskova et al., 2001). Hereby, the 
schematic structure of LMP-2A and its functional domains; as well as their associated 
proteins are presented in figure 1.6. 
 
Figure 1.6: Schematic structure of LMP-2A and its functional domains; as well as 
their associated proteins. (Young and Rickinson, 2004). 
 
1.6.2 Roles of LMP-2 
 In contrast to LMP-1, much less is known about LMP-2A/2B functions. The 12 
hydrophobic transmembrane domains of LMP-2 involve in localization of LMP-2 to the 
cell plasma membrane (Kieff and Rickinson, 2007). The cysteine rich C-terminal of 
LMP-2A is palmitoylated which is a process of post-translational modification, 
although the function is unnecessary for normal LMP-2A function (Higuchi et al., 2001; 
Katzman and Longnecker, 2004; Matskova et al., 2001). LMP-2 associates with lipid 
raft which may be important for initial contact of src family tyrosine kinases (Higuchi et 
al., 2001). Deletion studies prove that transmembrane domains and C-terminal domain 
are dispendable for in vitro B lymphocyte infection and growth transformation 
(Longnecker et al., 1993a; Longnecker et al., 1993b). 
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 LMP-2A N-terminal contains eight tyrosine residues and three of which are 
essential for BCR signaling blockade via phosphorylation (Fruehling et al., 1996; 
Fruehling et al., 1998; Fruehling and Longnecker, 1997). A mutation study shows that 
ITAM motif of LMP2A increases cellular phosphorylation and thus involves in signal 
transduction (Scholle et al., 2001).  
 LMP-2A interrupts BCR signaling and functions. A study shows that LMP-2A 
negatively regulates BCR signal through excluding it out from lipid raft and then 
targeting Src family tyrosine kinases (Lyn and Syk) for ubiquitin-dependant degradation 
(Dykstra et al., 2001; Ikeda et al., 2000). LMP-2A avoids protein tyrosine kinases 
(PTKs) from binding to BCR and thus prevents its activation. Moreover, LMP-2A 
blocks BCR activated calcium mobilization, tyrosine phoshorylation and gene 
transcriptional activation thus prevents EBV lytic activation and promotes cell growth 
of B-cells (Fruehling et al., 1996; Fruehling et al., 1998; Fruehling and Longnecker, 
1997; Miller et al., 1995; Winberg et al., 2000).  
 LMP-2A exploits ubiquitin-protein ligase for degradation of LMP-2A and its 
associated proteins Lyn for ubiquitination thus for internalization and degradation 
(Ikeda et al., 2000). Ubiquitin dependent degradation is an important process for 
regulating LMP-2A activity. Itchy, a Nedd ubiquitin ligase, binds and regulates LMP-
2A activity (Ikeda et al., 2000). When tyrosine residues are not phosphorylated, 
ubiquitin ligase will bind to the proline PY motifs of LMP-2A with its WW domains 
thus activates degradation (Ikeda et al., 2000). LMP-2A employs ubiquitin ligase for 
removing the excess LMP-2A. Recently, it has been proven that these processes involve 
in regulating Notch and Wnt pathway (Portis et al., 2004). In addition, LMP-2A might 
exploit Notch and Wnt pathway to regulate its function and maintain B-cell 
differentiation, activation and survival (Portis et al., 2004). 
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 In a recombinant EBV study, LMP-2A has been shown to down-regulate NFκB 
and STAT pathways in human carcinoma cell lines. There are down-regulation of NFκB 
and STAT3 activity due to LMP-2A suppression of LMP-1 expression thus reduces IL-
6 expression but not in LMP-2A negative cells (Stewart et al., 2004). The down 
regulation of NFκB and STAT activities are likely to contribute to diverse carcinoma 
and EBV-associated malignancies. For example, suppression of NFκB is able to induce 
epidermal hyperplasia which will contribute to the development of NPC (Seitz et al., 
1998).  
LMP-2A activates PI3K/Akt pathway thus enhances cell growth and anti-
apoptotic effect in B-cells, lymphoma, gastric carcinoma and epithelial cells (Portis and 
Longnecker, 2004; Scholle et al., 2000; Fukuda et al., 2001). Inhibition of PI3K/Akt 
triggers apoptosis in LMP-2A expressing Burkitt’s lymphoma and gastric carcinoma 
cell lines (Fukuda and Longnecker 2004). LMP-2A has been shown to activate 
PI3K/Akt via inhibition of TGF-β1 to induce caspase activity (Fukuda and Longnecker 
2004; Chen et al., 1998). Activation of PI3K/Akt is important in the development and 
progression of EBV-associated malignancy. In addition, activation of Ras/PI3K/Akt by 
LMP-2 will lead to unique genetic changes thus contributes to aggressive 
tumorigenicity (Scholle et al., 2000).  
LMP-2A is shown to activate MAPK pathway in EBV-infected cell lines in vitro 
(Chen et al., 2002; Portis and Longnecker, 2003; Panousis and Rowe, 1997). A 
transgenic mice study of LMP-2A shows that an activation of ERK/MAPK and 
PI3K/Akt to enhance proliferation and cell survival (Anderson and Longnecker, 2008). 
Another report also claims that LMP-2A activates ERK/MAPK and JNK/MAPK in 
NPC cell lines and thus promotes cell migration and invasion (Chen et al., 2002). 
Moreover, studies in Syk-null DT40 chicken B cells show that Syk is essential for 
activation of the ERK1 and JNK1 (Jiang et al., 1998). Although many studies prove that 
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LMP-2A activates MAPK pathway but the exact mechanisms still need to be studied.  
Although there are many research studied on EBV LMP-2A but little is currently known 
about the function of LMP-2B. As LMP-2B lacks of N-terminal of LMP-2A, LMP-2B 
is unlikely to share similar function as LMP-2A. Although many researches were 
conducted to study LMP-2 functions, but there are lack of report for involvement of 
LMP-2 in cell cycle arrest. 
 
1.7 Interaction of LMP-1, LMP-2A and LMP2B  
 EBV-encoded LMP-1, LMP-2A and LMP-2B are frequently co-expressed in 
many EBV-associated malignancies such as NPC, HD and immunoblastic lymphoma 
(Brooks et al., 1992; Deacon et al., 1993; Niedobitek et al., 1997; Rickinson and Kieff, 
2007). These proteins share some similarity in their protein structure and all involve in 
regulating signaling pathway. Since these proteins share some common identity 
therefore they might co-localize to a same cellular compartment (Longnecker and Kieff, 
1990; Lynch et al., 2002; Rovedo and Longnecker, 2007). Due to their co-localization 
and pathways inducing ability, there might be some form of interaction between these 
proteins and combinatorial roles played by these LM proteins.  
A study shows that LMP-2B modulates the activity of LMP-2A by preventing it 
from phosphorylation. LMP-2B contains similar C-terminal domain of LMP-2A, 
therefore it may prevent homodimerization of LMP-2A and subsequently inhibit its 
phosphorylation (Rovedo and Longnecker, 2007).  LMP-2B discrupts LMP-2A 
homodimers and recruits deubiquitinating enzyme which will in turn restore normal 
BCR signaling. Therefore, LMP-2B might act as a ―rheostat‖ for LMP-2A and BCR 
signaling (Rechsteiner et al., 2008).   
In addition, another study shows that LMP-2A augments the signaling of LMP-1 
to enhance NFκB and AP-1 pathway through extending LMP-1 turnover. Using a 
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coexpression study, LMP-2A has proven to modulate LMP-1 activities and that is not 
the consequence of direct interactions between the two proteins. Furthermore, LMP-2A, 
but not LMP-2B, modulates LMP-1 signalling pathway. LMP-2A increases the 
expression level of LMP-1 as well as increases its half-life (Dawson et al., 2001).  
 
1.8 Cell cycle regulation 
 The life cycle of a dividing cells can be divided into 4 stages; cell division 
occurs during mitosis (M); DNA and chromosomal replication phase (S) and gap 1 (G1) 
and gap 2 (G2) which separate the S and M phases. Additionally, during G1 phase, cells 
can exit cell cycle and enter (quiescent) G0 phase (Garrett, 2001).  
Movement of each phase of cell cycle is controlled or regulated by a number of 
positions known as checkpoint.  These checkpoints monitor cellular environment and 
make sure appropriate conditions have been fulfilled before it may enter each phase of 
cell cycle. These phases are controlled or monitored by a group of kinase complexes 
which consist of cyclin and cyclin dependent kinases (cdk) (Davy and Doorbar, 2007). 
These complexes are in turn regulated by multiple pathways that response to external 
stimuli and internal conditions of cells. A major function of these checkpoints is to 
maintain genome integrity throughout the cell cycle. The first of these checkpoints 
occurs at G1/S phase transition that is mainly to scan for DNA damage. The cells may 
also arrest in S phase due to DNA damage or incomplete DNA replication. Next, G2/M 
checkpoint, which monitors DNA replication and again screens for DNA damage just 
like G1/S checkpoint. This followed by spindle checkpoint, which is to make sure 
functional mitotic spindle has been formed correctly (Garrett, 2001). Besides cyclin and 
cdk, there are groups of gene known as cell cycle regulatory genes that can regulate 
normal cell cycle such as p53, p21, reprimo, Gadd45 and 14-3-3σ. Uncontrolled gene 
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expression of these regulators can interrupt normal cell cycle (Chang et al., 2003; Hata 
et al., 2005; Hermeking et al., 1997; Ohki et al., 2000; Wang and El-Deiry, 2006). 
A variety of viruses have been proved to be associated with G2/M arrest, 
including DNA viruses, RNA viruses and retroviruses which hijack a normal cell cycle 
for their life cycle but the methods used by these viruses to achieved this arrest appear 
to be very diverse (Davy and Doorbar, 2007). Further study may be required to 
determine the mechanism of this phenomenon.   
 
1.9 Objectives and Aims 
The aim of this project was to investigate the following hypothesis: 
 ―The interactions of LMP-1, LMP-2A and LMP-2B will cause changes in 
mRNA expression of cell cycle regulatory genes and interrupt normal cell cycle 
progression when over-express these latent membrane proteins thus cause physiological 
changes to the cells.‖  
 
In order to test this hypothesis, three main objectives were undertaken: 
1. To clone and express LMP-1, LMP-2A and LMP-2B in single and co-expression 
manner in HEK293T cell line. 
2. To examine the effects of LMP-1, LMP-2A and LMP-2B in mRNA expression 
of cell cycle genes.  
3. To examine the correlation of LMP-1, LMP-2A and LMP-2B with cell cycle 
progression. 
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2.1Cell lines and cell cultures 
2.1.1 Maintenance of cell lines 
Materials: 
1) Roswell Park Memorial Institute Medium (RPMI-1640) (GIBCO/BRL, Grand 
Island, NY)  
2) Dulbecco's Modified Eagle Medium (DMEM) (GIBCO/BRL, Grand Island, NY) 
3) Fetal bovine serum (FBS) (GIBCO/BRL, Grand Island, NY) 
4) Penicillin/streptomycin (10000 IU/ml penicillin and 10000 µg/ml streptomycin) 
(GIBCO/BRL, Grand Island, NY). 
5) TrypLETM Express (stable Trypsin Replacement (GIBCO/BRL, Grand Island, 
NY) 
6) Dimethyl Sulfoxide (DMSO) (Calbiochem/Merck KGaA Darmstadt, Germany) 
7) 0.4% (w/v) trypan blue (Sigma, USA) 
8) Phosphate Buffered Saline (PBS): 58 mM Na2HPO4, 17 mM NaH2PO4, 68 mM 
NaCl 
Methods: 
 B95.8 and HEK293T line obtained from ATCC® , USA (VR-1492™ and CRL-
11268™ respectively). B95.8 cell line was established by infection of EBV to marmoset 
monkey (Saguinus Oedipus) blood leukocytes (Miller and Lipman, 1973). B95.8 cell 
line was used as a source for LMP-1, LMP-2A and LMP-2B genes.  B95.8 was 
maintained in RPMI-1640 supplemented with 10% (v/v) FBS, 100 IU/ml penicillin and 
100 µg/ml streptomycin. 
 HEK293T cells which are widely used in molecular biology research for many 
years due to its viability and high transfection efficiency was maintained in DMEM 
supplemented with 10% (v/v) FBS, 100IU/ml penicillin and 100 µg/ml streptomycin. 
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All cells were maintained in an incubator (NuAire Inc., USA) at 37°C in 5% CO2 and 
sub-cultured in 1:10 ratio in the same condition unless for specific application.   
2.1.2 Cryopreservation and reviving cells 
  To store cells for long term, viable cells at the log phase of growth were 
trypsinized and centrifuged at 800 rpm for 5 minutes and resuspended in 
cryopreservation medium (RPMI-1640 supplemented with 20% FBS and 10% DMSO) 
at about 1x10
6
 cells/ml. One ml of cryopreservation medium was aliquoted to each 
cryovial (Nalgene).  The vials were placed in a NALGENE
TM
 Cryo 1°C freezing 
container and stored at -20ºC for 3 hours before freezing at -80ºC for overnight. It was 
transferred into the liquid nitrogen tank on the next day. 
 For reviving cells, a vial of cells was thawed immediately in a 37ºC water-bath.  
Eight ml of RPMI-1640 was used to wash the suspension cells in a 15 ml falcon tube 
followed by centrifugation (Sorvall RT6000) at 800 rpm for 5 minutes. The resulting 
pellet was resuspended in 5ml of RPMI-1640 supplemented with 20% FBS and 
transferred to T-25 culture flask (Nunclon, Denmark). The cells were incubated at 37ºC 
in a 5% CO2 environment. The growth rate of the culture was checked daily using 
inverted microscope (CK Olympus, Japan). 
 
2.1.3 Counting cells 
 Cell viability and concentration were determined using trypan blue incorporation. 
Fifty µl of cell suspension was mixed with 450 µl of 0.4% (w/v) trypan blue. Ten µl of 
the mixture was added to the chamber on haemacytometer. The unstained cells were 
counted by light microscope. The concentration of cells was determined with the 
formula below: 
Cell concentration (cells/ml) = n cells (counted viable cells) × 10
4
 × dilution factor 
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2.2 RNA extraction 
Materials 
1) RNeasy Protect Kit®  (Qiagen, Germany) 
2) β-mercaptoethanol (Sigma, USA) 
3) QIAshredder®  Homogenizer (Qiagen, Germany) 
4) Agarose gel, SeaKem®  LE (Cambrex, USA) 
5) Ethidium bromide (Sigma, USA) 
Methods: 
 RNA was extracted from cells that have been stabilized in RNAlater
®
 using the 
RNeasy Protect Kit
®
 according to manufacturer’s protocol. Briefly, cells were lysed in 
600 µl lysis buffer (Buffer RLT + 1% (v/v) β-mercaptoethanol) and the lysates were 
homogenized through QIAshredder
®
 spin-column homogenizer at 13000 rpm (Sigma 1-
14 minicentrifuge, USA) for 2 minutes. Then, 1 volume of 70% ethanol (600 µl) was 
added to the flow-through and mixed. The flow-through was then transferred to an 
RNeasy mini column and centrifuged at 11000 rpm for 15 seconds. The flow-through 
was discarded followed by washing with buffer RW1 (700 µl) and twice with RPE (500 
µl). The washing tubes were centrifuged at 11000 rpm for 15 seconds except the second 
wash of RPE at 13000 rpm for 2 minutes and the flow-through was discarded after each 
step. Finally, the RNeasy column was placed in a new tube and the RNA was eluted 
from the membrane with 50 µl of RNase-free water. The quality of the extracted RNA 
was checked using1% agarose gel stained with ethidium bromide.  The concentrations 
of the RNA were quantified using spectrophotometer (Shimazu, Japan). 
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2.3 Gene Cloning 
2.3.1 cDNA Synthesis 
Materials: 
1) SuperScriptTM III First-Strand Synthesis System for RT-PCR (Invitrogen, USA) 
Methods: 
 Total RNA from B95.8 cells was reverse transcribed (RT) to generate cDNA of 
LMP-1, LMP-2A and LMP-2B. Reverse transcription was performed using 
SuperScript
TM
 III First-Strand Synthesis System following the manufacturer’s protocol. 
Briefly, 5 µg of total RNA was mixed with 1 µl oligo(dT)20 (50 µM) and 1 µl of 10 mM 
dNTPs (2.5 mM each) in a final volume of 10 µl. The mixture was then incubated at 
65°C for 5 minutes and then placed on ice for 1 minute. Next, 10 µl of cDNA reaction 
mix [2 µl of 10×RT buffer, 4 µl of 25 mM MgCl2, 2 µl of 0.1 M DTT, 1 µl of 
RNaseOUT
TM
 (40 U/µl) and 1 µl of SuperScript
TM
 III RT (200 U/µl)] was added to the 
mixture and incubated for 50 minutes at 50°C. The reaction was terminated at 85°C for 
5 minutes. Finally, 1 µl of RNase H was added to the reaction and incubated at 37°C for 
20 minutes to remove the RNA template. 
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2.3.2 Polymerase Chain Reaction (PCR) 
Materials: 
1) i-pfu DNA polymerase (Intron Biotechnology, Seonggnam, Korea). 
Methods: 
 All PCRs in this study were performed on an ABI PCR 2720 thermocycler 
(Applied Biosystem, USA) using gene specific primers as listed in Table 2.1.  
Table 2.1: Genes-specific primers used in PCR. 
Name Sequences 
5’ - 3’ 
GC% bases Basic Tm (ºC) 
LMP1-F *CACCATGGAACACGACCTTGAGAGG 56 25 61 
LMP1-RS **TTAGTCATAGTAGCTTAGCTGAACTGGGCC 46.67 30 62 
LMP1-R GTCATAGTAGCTTAGCTGAACTGGGCC 51.85 27 61 
LMP2A-F *CACCATGGGGTCCCTAGAAATG 54.55 22 57 
LMP2A-RS **TTATACAGTGTTGCGATATGGGGTCG 46.15 26 58 
LMP2A-R TACAGTGTTGCGATATGGGGTC 50 22 55 
LMP2B-F *CACCATGAATCCAGTATGCCTGCCTG 53.85 26 61 
LMP2B-RS **TTATACAGTGTTGCGATATGGGGTCGGTGG 50 30 63 
LMP2B-R TACAGTGTTGCGATATGGGGTCGGTG 53.85 26 61 
 
*The bold and underlined residues represent the specific sequences require for 
directional cloning. 
**The bold and underlined residues represent the stop codon. 
The reactions were carried out in a total volume of 15 µl each reaction under optimized 
parameter as in Table 2.2. 
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Table 2.2: Components of PCR mixture and amplification conditions. 
Components Concentration of 
stock 
Working 
concentration 
One PCR 
reaction (μl) 
Amplification 
Conditions 
Ultra pure water 
(deionized water) 
- - 9.4 Denaturation (1×) 
94°C – 2 minutes 
 
Denaturation (40×) 
94°C – 20 seconds 
Annealing  
Tm°C – 15 seconds 
Extension  
72°C – 30 seconds 
 
Final extension (1×) 
72°C – 5 minutes 
 
10X i-pfu Buffer  
(Intron, Korea) 
10X 1X 1.5 
dNTPs (Intron, Korea) 10mM 0.8mM 1.2 
Forward primer 10μM 0.5μM 0.75 
Reverse primer 10μM 0.5μM 0.75 
i-pfu DNA 
polymerase (Intron, 
Korea) 
2.5U/μl 1U/15μl 0.4 
Template cDNA - - 1 
Total Volume   15 
 
 
2.3.3 Gene insertion to pcDNA3.1 vector 
Materials: 
1) pcDNA3.1 Directional TOPO cloning Kit (Invitrogen, USA) 
2) One Shot TOP10 chemically competent E.coli (Invitrogen, USA) 
3) LB agar: 1% (w/v) tryptone (BD, USA), 0.5% (w/v) yeast extract (BD, USA), 1% 
(w/v) NaCl (Merck, Germany), 1% (w/v) Bacto Agar powder (BD, USA) 
4) SOC medium: 2% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.05% (w/v) NaCl, 
0.5% MgSO4.7H2O and 20 mM glucose 
5) Ampicillin (Bioshop, Canada) 
Methods: 
 The LMP-1, LMP-2A and LMP-2B amplified products were cloned into 
pcDNA™3.1 Directional TOPO® vector. The pcDNA3.1 Directional TOPO expression 
vector is a linearized vector which provides greater than 90% efficiency of directional 
cloning of blunt-end PCR products into vector. In this system, PCR products are 
directionally cloned by adding CACC to the forward primer. The overhang with GTGG 
from the vector will invade to the double stranded PCR products and displacing the 
GTGG from the PCR products (Figure 2.1).   This vector employs topoisomerase I 
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activity to efficiently clone the PCR product into vector (Shuman, 1991 and Shuman, 
1994) thus forming a circular plasmid. The cloning site is located downstream of CMV 
promoter. There is no specific antibody for LMP-2B therefore for tagging of LMP-2B 
protein with V5 epitope and polyhistidine region, the termination codon was removed 
from the PCR primer. 
 
Figure 2.1: Multiple-cloning site (MCS) and Insertion site of pcDNA3.1 directional 
cloning vector.  
 Briefly, 4 µl of PCR product was mixed with 1 µl of salt solution (0.2 M NaCl 
and 0.01 M MgCl2) and 1 µl of vector (0.5 µg/µl). The cloning reaction mixture was left 
to incubate at room temperature for 5 minutes. Next, 2 µl of the mixture was added to 
the TOP10 chemically competent E. coli. Then, it underwent heat shock treatment at 
42°C for 30 seconds to transform the vector which carried the desired gene fragment 
into competent cells. Immediately after that, 250 µl of SOC medium was added to the 
transformants and incubated at 37°C for 1 hour. The heat shock method was described 
elsewhere (Sambrook et al., 1989). The E.coli tranformants were spread onto ampicillin 
selection plate (LB agar + 100 µg/ml ampicillin) and incubated at 37°C for 16 hours.  
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2.3.4 Boiling PCR for transformants 
Materials: 
1) Taq DNA polymerase (Finnzymes, Finland) 
2) Glycerol (Unilab, Australia) 
Methods: 
 Single colony was selected for boiling PCR assessments to verify insertion of 
the gene and orientation of inserted gene in the vector. A single colony was picked and 
added into the PCR master mix containing the components as mentioned in Section 
2.3.2 except for the DNA polymerase which was replaced with Taq DNA polymerase. 
In order to determine the correct insert and orientation of the genes, amplification was 
performed with the T7 forward primer (5’ TAATACGACTCACTATAGGG 3’) and 
insert-specific reverse primer (Table 2.1). The expected size of the amplicon will be 76-
bp longer when T7 forward primer was used. The colony with correct insert and 
orientation was cultured overnight and glycerol stocks were prepared (LB + 15% (v/v) 
glycerol) then stored at -80°C.  
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2.3.5 Plasmid Extraction 
Materials: 
1) QIAprep®  Spin Miniprep Kit (Qiagen, Germany) 
Methods: 
 Plasmid from the E.coli transformants was extracted using QIAprep®  Spin 
Miniprep Kit according to manufacturer’s protocol. Briefly, overnight 5 ml bacterial 
culture was harvested by centrifugation at 4000 rpm (Sigma 3-16PK) for 10 minutes. 
The bacterial pellet was resuspended with 250 µl of Buffer P1 and lysed with 250 µl of 
Buffer P2. The debris was precipitated with 350 µl of Buffer N3 and pelleted via 
centrifugation at 13000 rpm for 10 minutes. The supernatant was transferred into a spin 
column followed by centrifugation at 13000 rpm for 1 minute and the flow-through was 
discarded. The column was washed with 750 µl of Buffer PE and plasmid was eluted 
with 50 µl of Milli-Q water. Finally, the concentration and purity of plasmid DNA was 
checked through spectrophotometer and agarose gel electrophoresis. 
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2.3.6 Sequencing of Inserted Genes 
 The pcDNA3.1 recombinant vectors with correct insertions were sent to 
Advance Interactive Technologies (AIT) Pte. Ltd., Singapore for sequencing using T7 
and gene internal primers (Table 2.3). Then, the sequences were compared and aligned 
with Epstein-Barr virus (EBV) genome, strain B95-8 from NCBI (Gene Bank Acc. No.: 
V01555) using Molecular Evolutionary Genetics Analysis (MEGA) software version 
4.0 and Megalign (DNASTAR). 
Table 2.3: List of sequencing primers. 
Name Sequences (5’-3’) EBV 
coordinate 
bases Basic Tm 
(ºC) 
T7 TAATACGACTCACTATAGGG - 20 48 
S2-LMP1 TGCTGTTCATCTTCGGGTGC 169068-169049 20 54 
S3-LMP1 CTCTGCTCTCAAAACCTAGG 168612-168593 20 52 
S2-LMP2A ACATATACGAAGAAGCGGGC 166889-166908 20 52 
S3-LMP2A GACGCTGTTTTGCAGCTGAG 647-666 20 54 
S4-LMP2A CTGCATGTTATTACTGATTGTCGC 1287-1310 24 54 
S2-LMP2B TGCTCCTGATACTAGCGTAC 555-574 20 52 
S3-LMP2B ACTTCAAGAGTTTAAGCAGCAC 1161-1182 22 51 
BGH 
reverse 
TAGAAGGCACAGTCGAGG - 18 50 
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2.4 Expression of LMP-1, LMP-2A and LMP-2B 
Materials: 
1) Fugene®  HD Transfection Reagent (Roche, Switzerland) 
2) Opti-MEM®  (GIBCO/BRL, Grand Island, NY) 
3) pECFP-N1 (Clontech, USA) 
4) DMEM-10% FBS medium (as mentioned in Section 2.1) 
Methods: 
 LMP-1, LMP-2A and LMP-2B expressing cells were established by transfecting 
the cells with pcDNA3.1-LMP-1, pcDNA3.1-LMP-2A and pcDNA3.1-LMP-2B-V5 
constructs. The fluorescence protein expression vector, pcDNA3.1-CFP, was used to 
monitor the transfection efficiencies. Transfection of the epithelial cells was performed 
by Fugene
®
 HD Transfection Reagent following manufacturer’s protocol. Briefly, 
1×10
6
 cells were seeded in T-25 cell culture flask in DMEM-10 with no antibiotic and 
incubated for 24 hours at 37°C with 5% CO2. For transfection, 6 µg of plasmid (3 µg of 
pcDNA3.1-empty vector + 3 µg of pcDNA3.1-LMP-1 or pcDNA3.1-LMP-2A or 
pcDNA3.1-LMP-2B for the respective LMPs expression; 3 µg of pcDNA3.1-LMP-1 + 
3 µg of pcDNA3.1-LMP-2A or pcDNA3.1-LMP-2B-V5 for co-expression of LMPs) 
was added into 600 µl of opti-MEM
®
 medium. Subsequently, the diluted plasmid was 
added with 30 µl of Fugene
®
 HD Transfection Reagent (Roche, Switzerland) in a ratio 
of 1:5 and mixed well. The mixture was incubated for 15 minutes at room temperature 
for transfection-complex formation. Next, the transfection-complex was added into the 
seeded cells in drop-wise manner. The cells were incubated for 48 hours at 37°C with 5% 
CO2. After 48 hours incubation, the cells were harvested for downstream analysis. 
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2.5 Analysis of genes expressions in LMP-1, LMP-2A and LMP-2B expressing cells 
2.5.1 Analysis of RNA expression 
2.5.1.1 RNA extraction 
(As mentioned in Section 2.2) 
2.5.1.2 cDNA synthesis 
(As mentioned in Section 2.3.1) 
2.5.1.3 PCR 
Procedures were as mentioned in Section 2.3.2 but the forward primer was 
changed to S3-LMP1 for LMP-1 gene expression (453bp). For both LMP-2A and LMP-
2B, the same forward primer (S4-LMP-2A) was used to amplify the common sequences 
(316bp).  
2.5.1.4 Semi-quantitative RT-PCR 
 The synthesized cDNAs were quantitated with spectrophotometer and diluted to 
have the same concentration. The cDNA (700 ng) was subjected to semi-quantitative 
RT-PCR for comparison of the expressional levels of genes among different samples. 
The PCR composition and condition was described in Table 2.4. 
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Table 2.4: Components and conditions for semi-quantitative RT-PCR. 
  
The number of PCR cycles for each gene was optimized to ensure the 
amplification fall in the linear phase. Five µl of the PCR aliquots were removed and 
visualized after 15 cycles, 5 additional cycles will be carried out if it is not in linear 
phase. For each pair of genes specific primers (Table 2.5), three independent RT-PCRs 
were performed using three different set of RNA samples as template. RT-PCR for 
GAPDH (house-keeping gene) expression was used to normalize the amount of cDNA 
used. PCRs for GAPDH were performed as independent reactions. The PCR products 
were visualized in 2% (w/v) agarose gel and the intensity of the bands was quantified 
using Image J software.  
 
 
 
 
 
 
 
 
 
Components Concentration of 
stock 
Working 
concentration 
One PCR 
reaction (μl) 
Amplification 
Conditions 
Ultra pure water 
(deionized water) 
- - 15.0 Denaturation (1×) 
94°C – 2 minutes 
 
Denaturation  
94°C – 30 seconds 
Annealing  
Tm°C – 30 seconds 
Extension  
72°C – 30 seconds 
 
Final extension (1×) 
72°C – 5 minutes 
 
10× PCR Buffer 
(15mM MgCl2)  
10X 1X 2.0 
dNTPs 10mM 0.25mM 0.5 
Forward primer 10μM 0.25μM 0.5 
Reverse primer 10μM 0.25μM 0.5 
Taq DNA 
polymerase  
2U/μl 1U 0.5 
Template cDNA - - 1 
Total Volume   20 
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Table 2.5: List of Primers used for semi-quantitative RT-PCR. 
Gene Primer Sequence (5’-3’) Tm 
(°C) 
Product size 
(bp) 
Ref. 
14-3-3σ GGCCATGGACATCAGCAAGAA 
CGAAAGTGGTCTTGGCCAGAG 
58 137 Liu et al., 
2006 
p53 TGTCCCTTCCCAGAAAACCTACC 
CCACTCGGATAAGATGCTGAGGAG 
58 305 Wang and 
El-Deiry, 
2006 
p21 GTGGACCTGTCACTGTCTTGTAC 
CTTCCTCTTGGAGAAGATCAGC 
56 151 Hata, 
2005 
p27 AACGTGCGAGTGTCTAACGG 
CCCTCTAGGGGTTTGTGATTCT 
51 597 Weinmann 
et al., 
2008 
Reprimo GCAATCTGCTCATCAAGTCCGAG 
CCCCGCATTCCAAGTAAGTAGC 
58 384 Takahashi 
et al., 
2005 
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2.5.1.5 Real Time Quantitative PCR 
Materials: 
1) SYBR Green PCR Master Mix (Applied Biosystem, USA) 
Methods: 
 Real time quantitative PCR was performed in a volume of 15 µl reaction which 
contained 100 ng of cDNA template, 1×SYBR Green PCR Master mix and 0.1 mM 
forward and reverse gene specific primers using ABI 7000 Real time PCR machine 
(Applied Biosystem, USA). Each PCR reaction was optimized to eliminate the presence 
of primer dimer. For each pair of genes specific primers (Table 2.5), three independent 
RT-PCRs were performed using three different sets of RNA samples as template. The 
PCR conditions were as follows: 
1 cycle  : 95°C 10 mins 
40 cycles : Step 1 95°C, 15s 
   Step 2 60°C, 1min 
 
 The fluorescent product was determined at amplification step of each 
cycle. After amplification, melting curve was carried out by heating the PCR product to 
94°C for 5 mins and cooling at 0.5°C/10s to 55°C. The fluorescence data was collected 
at 0.5°C intervals. 
 The relative fold change of the gene of interest was determined by comparing its 
expression level to GAPDH or β-actin internal control as follows:  The relative fold 
change = 2
-ΔΔCq, where ΔΔCq= [[CqTarget (sample) – CqGAPDH (sample)] – [CqTarget 
(Empty vector) – CqGAPDH (empty vector)]+ [CqTarget (sample) – Cqβ-actin (sample)] – 
[CqTarget (Empty vector) – Cqβ-actin (empty vector)]]/2. Cq is quantification cycle 
according to Bustin et al., (2009). Primers for GAPDH (Forward-5’ CCA CCC ATG 
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GCA AAT TCC 3’ and Reverse-5’ CAG CAT CGC CCC ACT TG 3’), β-actin 
(Forward-5’ AAA AGC CAC CCC ACT TCT CTC T 3’ and Reverse-5’ AAT GCT 
ATC ACC TCC CCT GTG T 3’), 14-3-3σ (Forward-5’ TGT CCA GTA TTG AGC 
AGA AAA GCA 3’ and Reverse-5’ CAC GCC CTG GAG CTC AGT 3’) and Reprimo 
(Forward-5’ CTG GCC CTG GGA CAA AGA C 3’ and Reverse-5’ TCA AAA CGG 
TGT CAC GGA TGT 3’), were designed using Primer express 3.0. 
 
2.5.2 Analysis of protein by Western blotting 
2.5.2.1 Protein extraction 
Materials: 
1) Radio-immuno-precipitation assay (RIPA) buffer: 50 mM Tris-Cl (Sigma, USA), 
150 mM NaCl (Merck, Germany), 0.5% (w/v) Na-deoxycholate (Sigma, USA), 
0.1% (w/v) Sodium dodecyl sulphate (SDS) (Amresco, Ohio), 1% (v/v) NP-40 
(Sigma, USA). 
2) Protease inhibitor cocktail set I (Calbiochem, La Jolla, CA) 
3) Phosphatase inhibitor cocktail set V, 50× (Calbiochem, La Jolla, CA) 
Methods: 
 The transfected cells in T-25 plate were washed with ice-cold PBS and harvested 
with cell scraper. After centrifugation at 800 rpm for 5 minutes, the supernatant was 
discarded. Then, 194 µl of RIPA buffer was added to the pellet with 2 µl of protease 
inhibitor cocktail and 4 µl of phosphatase inhibitor then transferred to a 1.5 ml 
Eppendorf tube. The cell lysate was incubated for 30 minutes on ice and mixed 
thoroughly every 5 minutes. After the incubation, the cell lysate was centrifuged at 
13000 rpm for 30 minutes at 4°C. The supernatant was collected and stored at -20°C 
before use. 
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2.5.2.2 Bradford assay 
Materials: 
1) Bradford Protein Assay (Bio-Rad, USA) 
2) Bovine Serum Albumin (BSA) (Bio-Rad, USA) 
Methods: 
 Cell lysate was quantified with Bradford’s method with improved dye reagent 
from Bio-Rad. Six concentrations of BSA (0, 0.1, 0.2, 0.3, 0.4, 0.5 mg/ml) were 
prepared in 10µl each in duplicate in microtiter plate to act as a standard for protein 
concentration measurement. The sample was prepared in 10× dilution and 20× dilution. 
A 200 µl of Bradford dye reagent was added to each well and mixed. The plate was 
incubated for 5 minutes in room temperature to allow colour development. The optical 
density at 590 nm for each sample was collected from MRX microplate reader (Dynex, 
Chantilly, VA). The protein concentration for each sample was determined from the 
standard curve. 
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2.5.2.3 SDS-PAGE Electrophoresis 
Materials:   
1) Monomer solution (30.8% T 2.7%CBis): For 200 ml solution; 60 g acrylamide 
(Sigma, USA), 1.6 g N,N’-methylenebisacrylamide (Sigma, USA). 
2) Running gel buffer (4×): 1.5 M Tris-Cl, pH 8.8 
3) Stacking gel buffer (4×): 0.5 M Tris-Cl, pH 6.8 
4) SDS (10% w/v) 
5) Ammonium Persulphate (APS) (10% w/v) (Fluka, Switzerland) 
6) Tetramethylethylenediamine (TEMED) (Fluka, Switzerland) 
7) Sample treatment buffer (6×): 7 ml 0.5M Tris-Cl (pH 6.8), 2.6 ml Glycerol, 1 g 
1,4-Dithio-DL-threitol (DTT), 60 µl of 10% (w/v) Bromophenol Blue, 400 ul 10% 
(w/v) SDS 
8) Gel Running Buffer (10×): 0.25 M TRis-HCl, 1.9 M Glycine (Sigma, USA), 1% 
(w/v) SDS, pH 8.6 
9) PageRuler™ Prestained Protein ladder (Fermentas, Canada) 
Methods: 
 The extracted proteins were mixed with 6× sample treatment buffer and heat 
denatured at 94°C for 5 minutes (at 70°C for 5 minutes for LMP2-A and LMP-2B). 
Fifty µg of the protein was loaded on a 12% SDS polyacrylamide gel for separation 
(Table 2.6). Five µl of PageRuler™ Prestained Protein ladder was used as molecular 
weight marker.  
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Table 2.6: Components of the running gel and stacking gel. 
Reagents 12% running gel 10% running gel 4% stacking gel 
Monomer solution 3.2 ml 2.67 ml 665µl 
Gel buffer 2.00 ml 2.00 ml 1.25 ml 
10% SDS 80 µl 80 µl 50 µl 
Mili-Q 2.8 ml 3.33 ml 3.0 ml 
10% APS 120 µl 120 µl 50 µl 
TEMED 8 µl 8 µl 5 µl 
 
The gel percentage was dependent on the molecular weight of the interested protein. 
The protein separation was performed in a Mini-PROTEAN
®
 3 cell (Bio-rad) with 1× 
gel running buffer. Electrophoresis was achieved with 100V for 140 minutes at 4°C.  
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2.5.2.4 Immunoblotting 
Materials: 
1) Polyvinylidene Flouride (PVDF) membrane (PALL Corporation, Pensacola) 
2) Methanol (R&M marketing, Essex, United Kingdom) 
3) Tween-20 (Sigma® , USA) 
4) Blocking solution: milk diluents (KPL, Inc., Gaithersburg, MD) 
5) 5-bromo-4chloro-3indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) 
Phophatase Substrate System (KPL, Inc., Gaithersburg, MD)  
6) Western Lightning®  Plus–ECL (Perkin Elmer, USA) 
7) 1× Tris Buffered Saline (TBS): 5 mM Tris-HCI, pH7.5, 150 mM NaCl 
Methods:  
After separating proteins using SDS-PAGE, the proteins were transferred 
electrophoretically to a PVDF membrane using Trans-Blot®  SD Semi-Dry 
Electrophoretic Transfer Cell (Bio-Rad) for 25 minutes at 12V. The transfer efficiency 
was determined by observing the prestained ladder. After a complete transfer, the 
membrane was washed with TBST buffer (0.1% tween-20 in TBS) for 10 minutes and 
blocked with blocking solution (0.2% non-fat milk in TBST) for 1 hour at room 
temperature. Then, it was probed with primary antibody at room temperature for one 
hour. After washing for 3 times with TBST for 5 minutes, the membrane was probed 
with secondary antibody for 1 hour. After washing 3 times with TBST for 5 minutes, 
the protein signal was detected with BCIP/NBT phosphate substrate system at room 
temperature for 10 minutes for AP-conjugated secondary antibody. For HRP-conjugated 
secondary antibody, protein signal was detected by Western Lightning®  Plus–ECL 
detection system according to manufacturer’s protocol. The list of antibodies used and 
dilution for each antibody are described in Table 2.7. 
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Table 2.7: List of Antibodies used in Western blotting. 
Antibodies Dilution  
(in 0.1% non-fat milk) 
Manufacturer 
CS1-4 LMP1 1:1000 Dako, Denmark 
B14-7 LMP-2A 1:1000 Serotec, UK 
V5 epitope 1:1000 Invitrogen, USA 
Alpha-Tubulin 1:1000 Abnova, Taiwan 
14-3-3 sigma 1:1000 Abnova, Taiwan 
Reprimo 1:1000 Genetex, USA 
HRP-anti mouse/ rat 1:2000 Dako, Denmark 
AP-anti mouse 1:5000 Sigma, USA 
HRP-anti rabbit 1:1000 Abnova, Taiwan 
HRP-anti Goat 1:1000 Abnova, Taiwan 
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2.6 Flow cytometry for cell cycle Analysis 
Materials: 
1) Propidium iodide (Sigma, USA) 
2) RNase A solution (Novagen, EMD Biosciences, Inc, Madison, WI) 
Methods: 
 Forty-eight hours after transfection, the cells were harvested prior to propidium 
iodide staining. The cells were trypsinized and washed twice with PBS, then collected 
in 15ml round bottom tube (Becto Dickinson, San Jose, CA). Next, the cells were fixed 
in ice-cold absolute ethanol at 4°C for 1 hour and then collected by centrifugation. The 
pellet was washed once with PBS and incubated for 5 minutes on ice in 5ml of PBS 
with 0.25% Triton-X 100. The cells were then collected and incubated in PBS 
containing 10 µg/ml propidium iodide and 10 µg/ml RNaseA at 4°C for 20 minutes. 
The cells were kept in 4°C prior to FACS analysis using FACS Calibur flow cytometer 
(Becto Dickinson San Jose, CA). The histograms from FACS were generated with 
Winmbi and further analyzed with Cylchred cell cycle analysis software. 
 
2.7 Data Analysis 
 All collected data were evaluated with Graphpad PRISM 5.0. Results for 
semiquantitative PCR and qPCR were evaluated with student’s t-test and results from 
flow cytometry were evaluated with ANOVA. All statistical tests with P-values < 0.05 
were considered statistically significant. 
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3.1 Cloning and sequence analysis of LMP-1, 2A and 2B derived from B95.8 cells 
Overexpression of LMP-1 may contribute to cytostatic effect to the expressing cells. 
Therefore, to evaluate the effects of LMPs on cell cycle regulation, we first constructed 
the expression vector (pcDNA3.1) that allowed expression of LMPs under the control of 
CMV promoter. 
LMP-1, 2A and 2B genes for cloning were derived from B95.8 cell line. The 
total RNA (Figure 3.1A) was first subjected to cDNA synthesis and followed by PCR to 
amplify the genes (Figure 3.1B) prior to cloning into pcDNA3.1 vector (Appendix A).  
LMP-1, 2A and 2B PCR products were ligated into pcDNA3.1 vector with 
topoisomerase activity and transformed into E.coli. The recombinant plasmids were 
purified from the positive transformants which were first verified using colony PCR to 
confirm the presence of inserts with correct  sizes (Figure 3.2). The sequences of the 
inserted genes in the extracted plasmids were confirmed by sequencing reactions. 
Subsequently, the sequences were compared to Epstein-Barr virus (EBV) genome, 
strain B95.8 in NCBI database (GenBank Acc. No.: V01555). The sequences of the 
inserted genes perfectly matched with the sequences of LMP-1, LMP-2A and LMP-2B 
in EBV B95.8 strain (Appendix B). 
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Figure 3.1: RT-PCR and cloning of LMP-1, 2A and 2B derived from B95.8 cell 
line. (A) Gel electrophoresis of total RNA isolated from B95.8 cell line with 
GeneRuler™ DNA Ladder Mix (Fermentas) as a size indicator in lane 1. (B) RT-PCR 
amplification of LMP-1, 1158bp (Lane 2), LMP-2A, 1491bp (Lane 3) and LMP-2B, 
1134bp (Lane 4) with GeneRuler™ 100 bp plus DNA Ladder (Fermentas) as a size 
indicator in lane 1. 
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Figure 3.2: Verification of gene insertion into pcDNA3.1 with T7 and BGH 
primers. Lane 1: Fermentas GeneRuler™ 100 bp Plus DNA Ladder, Lane 2: 
pcDNA3.1-LMP1 (1414bp), Lane 3: pcDNA3.1-LMP2A (1747bp), Lane 4: pcDNA3.1-
LMP2B (1387bp), Lane 5: pcDNA3.1-empty vector (249bp), Lane 6: Negative control 
(PCR reaction without template), Lane 7: Fermentas GeneRuler™ 100 bp Plus DNA 
Ladder. 
 
3.2 Transfection optimization 
HEK293T is widely used to express and study LMPs properties. In order to study the 
LMPs cytostatic effect, these LMPs must be able to achieve their optimal expression 
levels. Before transfection of LMPs constructs, the efficiency of pcDNA3.1 gene 
delivery system was optimized using cyan fluorescent protein (CFP). The cyan 
fluorescent gene from fluorescent CFP-expressing plasmid, pECFP-N1 
(Clontech,USA), was subcloned into pcDNA3.1 vector and subsequently transfected 
into HEK293T cells for determining the optimum ratio of plasmid DNA to Fugene® HD 
transfection reagent. The transfection efficiency of about 70% was obtained by using 
                  1          2         3          4         5          6          7 
1000bp 
500bp 
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the ratio of 1:5 (1µg DNA to 5µl of Fugene® HD) in which  about 70% of the cells 
expressed the CFP at 24 hours after transfection (compare Fig 3.3A and B). 
 
A          B 
 
 
Figure 3.3: Transfection of HEK293T cells with the amount of pcDNA3.1-CFP (µg) 
to Fugene HD (µl) at the ratio of 1:5. 100× magnification revealing intracellular CFP 
expression. (A) Cells transfected with pcDNA3.1-CFP. (B) Bright field picture of 
transfected cells. 
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3.3 Expression of LMP-1, LMP-2A, LMP-2B in HEK293T cell line 
After optimization of the gene delivery system, the recombinant plasmids were 
transfected into HEK293T cells to express the LMPs. The expression levels of these 
LMPs were verified by RT-PCR and western blotting.  
By RT-PCR, the expressions of LMP-1, LMP-2A and LMP-2B mRNA were 
detected in HEK293T cells (Figure 3.4) after transient transfection. Forty-eight hours 
post-transfection, the cDNAs from transfected cells were subjected to RT-PCR using 
gene specific primers and the products were analyzed via agarose gel eletrophoresis. As 
shown in Figure 3.4, all the transfected cells expressed LMPs at a detectable level 
except cells transfected with pcDNA3.1-empty vector. 
 
 
 
Figure 3.4: Transcription of LMP-1 and LMP-2 in HEK293T. Both LMP-2A and 
LMP-2B share a common sequence therefore the same primer pair was used to verify 
the expression of LMP-2. Same amount of cDNAs were subjected to semi-quantitative 
PCR and the amplified products were analyzed using 1% agarose gel electrophoresis. 
The cDNA from B95.8 cells was used as a positive control for LMPs gene expression. 
GAPDH was used as an internal control for cDNA abundance normalization. 
LMP-1 
LMP-2 
GAPDH 
453 bp 
316 bp 
449 bp 
B
9
5
.8
 
L
M
P
-1
 
L
M
P
-2
A
 
L
M
P
-2
B
 
L
M
P
-1
, 
2
A
 
L
M
P
-1
, 
2
B
 
L
M
P
-2
A
, 
2
B
  
E
m
p
ty
 V
ec
to
r 
N
eg
at
iv
e 
 
Chapter 3  Results 
51 
 
The expression of LMPs proteins in the transfected cells was further confirmed 
using western blot assay at 48 hours after transfection (Figure 3.5). Western blot 
analysis revealed that LMPs with the molecular weights of 63kDa, 53kDa and 45kDa 
were expressed in cells transfected with pcDNA3.1-LMP-1, pcDNA3.1-LMP-2A and 
pcDNA3.1-LMP-2B-V5 constructs respectively. These observations indicated that the 
expression vectors were successfully transfected into cells and expressed LMPs at 
detectable levels.    
 
 
 
 
                                         
Figure 3.5: Detection of LMPs protein expression in HEK293T after transfection 
with various pcDNA3.1 constructs. Fifty µg of total protein lysates were separated in 
10% SDS-PAGE and transferred to  PVDF membranes for blotting with anti-LMP1 
(CS1-4), anti-LMP2A (14B7) and anti-V5 antibodies to detect LMP1, LMP2A 
andLMP-2B proteins respectively. B95.8 cell lysate was used as a positive control for 
LMP-1 and LMP-2A proteins. 
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3.4 Reduction in cell density in all LMP-1 expressing cells 
LMP-1 is toxic to cells and causes cytostasis when expressed in high levels 
(Hammerschmidt et al., 1989; Floettmann et al., 1996). Indeed, forty-eight hours post-
transfection, cells were examined microscopically for effects of LMPs expression on 
cell viability. We observed reduction in cell density in all LMP-1 expressing cells 
(Figure 3.6) 48 hours post-transfection. There were less or no obvious phenotypical 
changes observed in other cells compared to their control cells. The control cells 
(pcDNA3.1-empty vector) showed a typical appearance of epithelial cells with flattened 
cell morphology and exhibited clear cell-to-cell contact and adhesion. 
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Figure 3.6: Effects of LMPs expression on cell viability and morphology. The LMP-
1 expressing cells contain lesser cells compared to the cells transfected with empty 
vector. (Scale bar, 100µm). 
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3.5 Upregulation of 14-3-3σ and Reprimo in LMP-1 expressing cells from semi-
quantitative RT-PCR analysis 
Due to the observation of a reduced cell density in all LMP-1 expressing cells, we 
further explored the effect of LMP-1 on cell cycle progression. The mRNA levels of 
several cell cycle regulator genes were analyzed in LMPs expressing cells by semi-
quantitative RT-PCR. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene 
was used as an internal control. There were no significant changes in the transcription of 
p53, p27 and p21 among all the transfected cells (Figure 3.7A). However, 14-3-3σ and 
Reprimo which are mediators for G2 cell cycle arrest (Hermeking et al., 1997; Ohki et 
al., 2000) showed significant upregulation in all LMP-1 expressing cells with about 2 
folds, compared to negative control (pcDNA3.1-empty vector) (Figure 3.7). There are 
no significant changes of these gene expression levels in LMP-2A, LMP-2B and LMP-
2A, 2B expressing cells. The fold change of each gene is summarized in Figure 3.7B. 
Expression levels of 14-3-3σ and Reprimo were further analyzed with real-time 
quantitative PCR. 
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Figure 3.7, continued. 
 
Figure 3.7: Semi-quantitative comparison of mRNA expression levels of p53, p27, 
p21, Reprimo and 14-3-3σ in LMPs expressing cells.(A) Gel electrophoresis of the 
RT-PCR products. (B) Relative transcripts levels for all the transfected cells. Total RNA 
was reverse-transcribed and cDNAs were subjected to semi-quantitative PCR and the 
amplified products were analyzed using 1.5% agarose gel electrophoresis. GAPDH was 
used as internal control for cDNA abundance normalization. The densitometric value of 
each amplified products was normalized to negative control (pcDNA3.1-empty vector). 
Data shown are the mean of three independent experiments with standard error as error 
bars. *Indicates where value is significant in comparison to negative control 
(pcDNA3.1-empty vector) (student’s t-test, *=p<0.05). Data are representative of three 
or more independent experiments. 
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3.6 Upregulation of 14-3-3σ and Reprimo in LMP-1 expressing cells from real-time 
quantitative PCR assay 
The upregulation of 14-3-3σ and Reprimo was further analyzed with real-time PCR 
assay. GAPDH and β-actin were used as endogenous controls. Values for Relative 
Quantitative (RQ) were determined from the Cq of each reaction. In order to determine 
specific amplification, melting curves of the PCR products were studied and only single 
peak for all amplifications were observed (Figure 3.8). Upregulation of these genes 
were confirmed in all the LMP-1 expressing cells (Figure 3.9).  The gene expression of 
14-3-3σ was upregulated in LMP-1, LMP-1, 2A and LMP-1, 2B expressing cells by 
3.49 fold (p<0.05), 2.78 fold (p<0.05) and 2.39 fold (p<0.05), respectively when 
compared to the empty vector. Reprimo was upregulated by 2.08 fold (p<0.05), 2.27 
fold (p<0.05) and 1.76 fold (p<0.05), respectively when compared to the empty vector. 
Once again, these upregulation of genes were not observed in LMP-2A, LMP-2B and 
LMP-2A, 2B expressing cells. 
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Figure 3.8, continued. 
 
 
Figure 3.8: Melting curve profiles for PCR amplifications of GAPDH, β-actin, 14-3-
3σ and Reprimo. Only single peak was observed in all amplification reactions. 
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Figure 3.9: The relative mRNAs expressions of 14-3-3σ and Reprimo in LMPs 
expressing cells. Relative gene expression levels for all the transfected cells were 
determined using real-time quantitative analysis. Data shown are the mean of three 
independent experiments with standard error as error bars. *Indicates where value is 
significant in comparison to negative control (pcDNA3.1-empty vector) (Student’s t-
test, *=p<0.05). Data are representative of three or more independent experiments. 
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3.7 14-3-3σ and Reprimo proteins were upregulated in all the LMP-1 expressing 
cells 
In this study, the protein expression levels of 14-3-3σ and Reprimo were further 
examined with specific antibodies via western blotting analysis. As shown in Figure 
3.10, protein levels of 14-3-3σ and Reprimo were upregulated in all the LMP-1 
expressing cells.  
 
 
 
    
     
     
 
Figure 3.10: Western blotting analysis of 14-3-3σ and Reprimo in all the 
transfected cells. Cells transfected with empty vector were used as a negative control. 
Fifty µg of total protein lysates were separated in 12% SDS-PAGE and transferred to 
PVDF membranes for blotting with specific antibodies. Protein levels for 14-3-3σ and 
Reprimo in the various transfected cells were shown and α- tubulin protein level was 
detected as loading control. 
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3.8 Overexpression of LMP-1 arrests cells in G₂/M phase 
In order to understand the effects of LMPs expression on cell cycle progression, 
transfected cells were subjected to flow cytometry analysis based on DNA content in 
nuclei stained by PI. Forty-eight hours post-transfection, cell cycle analysis revealed an 
increase in G₂/M phase in all the LMP-1 expressing cells compared to the control cells 
(Figure 3.11). Our data has shown that about 25.13% ± 3.93% (p<0.05) of the cells 
expressing only LMP-1 accumulated in G₂/M phase 48 hours after transfection, in 
contrast to only about 16.73% ± 0.26% of negative control cells (pcDNA3.1-empty 
vector) in the same phase. When LMP-1 was coexpressed with LMP-2A or LMP-2B, 
the proportion of cells accumulated in G₂/M phase were 25.93% ± 1.07% (p<0.01) and 
24.97% ± 3.88% (p<0.05), respectively (Figure 3.11B and Table 3.1). The results 
revealed that the overexpression of LMP-1 capable to arrest the cells in G₂/M phase. 
Interestingly, there are some increments of cells in sub G1 phase of LMP-1 expressing 
cells that maybe due to the cytotoxic effect of LMP-1 (Hammerschmidt et al., 1989). In 
contrast, LMP-2A and LMP-2B had no effects on cell cycle progression when express 
alone or coexpress with each other and LMP-1. Details of cell cycle distributions for 
transfected cells and HEK293T cells are summarized in Table 3.1. 
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Figure 3.11, continued. 
 
Figure 3.11: Flow cytometry analysis of HEK293T cells. (A) Histograms represent 
cell cycle distributions of HEK293T cells transfected with LMPs constructs and non-
transfected parental cells. DNA profiles were analyzed using Cylchred software. G1 and 
G2/M phases are shown in red, and S phase is shown in green. The arrow indicates the 
apoptotic-sub G1fraction of the cells. (B) Cell cycle phase distribution was analysed. 
Transfected cells were compared to cells transfected with pcDNA3.1 empty vector 
(mock). Data shown are the mean of three independent experiments with standard error 
as error bars. *Indicates where value is significant in comparison to negative control 
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(pcDNA3.1-empty vector) (ANOVA,**=p<0.01; *=p<0.05). Data are representative of 
three or more independent experiments. 
 
Table 3.1: Cell Cycle distribution of transfected cells and HEK293T cells. 
Clones G0/G1(%) SD 
(%) 
S 
(%) 
SD 
(%) 
G2/M (%) SD 
(%) 
Total 
LMP-1 34.40 4.43 40.47 1.82 25.13* 3.93 100.00 
LMP-2A 35.93 6.09 46.07 6.03 18.00 1.23 100.00 
LMP-2B 31.97 1.50 50.23 2.37 17.80 0.95 100.00 
LMP-1,2A 32.77 0.67 41.30 1.61 25.93** 1.07 100.00 
LMP-1,2B 33.20 0.46 41.83 4.11 24.97* 3.88 100.00 
LMP-2A,2B 34.07 3.36 49.03 1.52 16.87 4.47 100.00 
Empty Vector 37.47 5.48 45.80 5.51 16.73 0.26 100.00 
HEK293T 39.60 6.19 42.70 8.70 17.70 2.74 100.00 
 
*Indicates where value is significant in comparison to control (ANOVA,**=p<0.01 
*=p<0.05). 
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4.1 Expression of LMPs  
There are 2 sub-types of EBV, Type I and Type II. Type I is represented by the 
prototype B95.8 strain while Type 2 was firstly dicovered to be associated with some 
cases of Burkitt’s lymphomas in central Africa and New Guinea. The LMPs genes for 
our study were derived from B95.8 EBV strain. For LMP-1 itself, there are many 
sequence variations derived from different patients nowaday. In 1991, Hu and co-
workers discovered a different sequence of LMP-1 from the Chinese NPC patients that 
is different in the loss of XhoI restriction site in the N-terminal and the 30-bp deletion 
adjacent to the CTAR2 domain compared to prototype B95.8. This variant is also 
known as CAOLMP-1. To date, there are many NPC-derived LMP-1 variants have been 
isolated from Asia and Europe. One of these LMP-1 variants is NLMP-1 that derived 
from NPC patient from Taiwan. NLMP-1 was reported to be more potent in 
transforming rodent fibroblast and able to induce tumor in nude mice as compared to 
B95.8 prototype (Chen et al., 1992). In another experiment, NLMP-1 expressing Balb/c 
3T3 cells was shown to produce lower level of nitric oxide that eventually can lead to 
cellular apoptosis as compared to wild type LMP-1. This ability of NLMP-1 may be an 
important contribution for cell survival (Yoshizaki et al., 2001). Other NPC LMP-1 
variants such as C15 was isolated from Mediterranean Caucasian (Gilligan et al., 1990); 
LMP-1 Groups A-D European NPC (Sandvej et al.,1997); 2117-LMP-1 isolated from 
Hong Kong (Huang et al., 1989), DV-Arg335 and DV-Gly335 also isolated from Hong 
Kong (Cheung et al., 1998) and NPC-7 which isolated from China (Midgley et al., 
2000).  In Malaysia, only limited LMP1 sequences  isolated from patients with 
nasopharyngeal carcinoma has been reported (Tan et al., 2007). Different clinical 
variants are likely to have variation in the functions of the LMP-1 genes. The selection 
of LMP-1 strains or variants for study should be under careful consideration. For our 
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study, the wild-type LMPs sequences from EBV B95.8 were selected with the 
consideration of the integrity of the genome as a major prototype of EBV strain.  
Next, LMP-1 contains both oncogenic and toxic properties; therefore, there was 
a need to develop appropriate method to express LMP-1. In order to induce cytostatic 
effect which caused by LMP-1 and study LMPs interaction in cell cycle arrest, it must 
be expressed efficiently in the cells. Therefore, a few considerations were taken when 
carried out the study. The pcDNA3.1 mammalian expression vector was selected due to 
its human cytomegalovirus (CMV) immediate early enhancer/promoter which is 
capable for high-level constitutive expression of the gene of interest in a wide range of 
mammalian cells lines (Anderson, et al., 1989; Boshart et al., 1985; Nelson et al., 
1987). The HEK293T is a derivative of HEK293 line transfected with SV40 T-antigen 
which is important for rapidly ampliflying plasmid containing SV40 origin of 
replication such as pcDNA3.1 (Gluzman, 1981).  SV40 plasmids undergo multiple 
rounds of duplication within one cell generation, usually accumulating to over 10,000 
plasmid copies per cell in just 48 h after transfection (Chittenden et al., 1991). Due to 
these criteria, LMPs were successfully expressed at high level compared to its 
endogenous expression level in B95.8 (Figure 3.5).   
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4.2 Overexpression of LMP-1 Induces Cell cycle Arrest 
LMP-1 is a typical oncogene that is capable to transform rodent fibroblast (Wang et al., 
1985). However, LMP-1 is also able to inhibit cell proliferation or induce cytostatic 
effect when expressed in high level (Cuomo et al., 1992, Floettmann et al., 1996; 
Hammerschmidt et al., 1989; Kaykas and Sugden, 2000). When LMP-1 was over-
expressed in one to four times higher than its endogenous expression level in EBV-
positive B cells, cytostasis in HEK293 cells for at least 6 days was induced (Kaykas and 
Sugden, 2000). Floettmann et al. (1996) also showed that LMP-1 induced cytostatic 
effect in BJAB, DG75 and Akata cells but some of the cells resumed proliferation after 
4 days. The recovered cells may be part of the cells with lower expression level of 
LMP-1. Hence, LMP-1 may have growth advantage in those cells with lower expression 
levels.  
In our present study, we demonstrated that LMP-1 expressing HEK293T cells 
exhibited cytostatic effect when expressed in higher level than B95.8 cells. This was 
evident from the observation of a reduction in cell density in the LMP-1 expressing cells 
(Figure 3.6).   Moreover, in agreement with Floettmann et al. (1996) and Deng et al. 
(2003), our flow cytometry analysis (Figure 3.11) further revealed that LMP-1 is able to 
influence cell cycle progression and arrested cells at the G2/M phase of the cell cycle.  
The cytostatic effect of cellular components or drugs can cause the cell to stop growing 
and it will usually followed by either cytotoxicity or escape from the stasis. From our 
observation (Figure 3.11), LMP-1 induced some cytotoxicity that caused the cells to 
undergo cell death and that may be the consequences of the cytostatic effect. 
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In constrast, LMP-2A and LMP-2B are unable to induce any changes in cell 
cycle progression. This suggested that LMP-2A and LMP-2B may not have any effect 
on cell cycle progression. Furthermore, LMP-2A and LMP-2B also unable to induce 
any significant changes to the cytostatic effect of LMP-1 and this can be further 
suggested that LMP-2 may not be an interaction partner for LMP-1 to activate 
cytostasis. 
There are possible consequences of this LMP-1 induce cytostasis. Upon 
infection of primary B-cells, EBV DNA is replicated rapidly and this amplification is 
thought to be vital in maintaining an optimal level of viral gene expression. Eventually, 
the number of DNA copies stabilizes. The stabilization may be caused by LMP-1’s role 
in growth inhibition whereby a higher LMP-1 expression level restricts cell proliferation 
(Kaykas and Sugden, 2000). In Burkitt’s lymphoma, one of the fastest proliferating 
human tumors, the expression of LMP-1 is lost (Rowe et al., 1987). The rapid 
proliferation of this tumor may be contributed by the loss of LMP-1’s growth inhibitory 
properties. In addition, the susceptibility of EBV infected cells to exterior cytotoxic 
signals such as chemotherapy drug (Cisplatin, Doxorubicin and Fluorouracil) that may 
be limited by the system which LMP-1 employs to induce cytostasis (Kaykas and 
Sugden, 2000).   
Besides LMP-1, multiple oncogenes have been proved to induce both growth-
promoting and growth-inhibitory effects. This paradox effects are observed in cellular 
oncoprotein Ras, c-Myc and Bcl-2 and the viral oncoproteins E1A and E7. These 
oncoproteins have significant role in promoting cell proliferation or survival. However, 
under certain circumstances, these oncoproteins are able to suppress cell proliferation 
either by cell cycle arrest or induction of p53-dependent and -independent apoptosis 
(Evan et al., 1992; Debbas and White, 1993; Howes et al., 1994; O'Reilly et al., 1996; 
Serrano et al., 1997; Evan and Littlewood, 1998). Moreover, these oncoproteins are able 
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to suppress its oncogenic properties via specific mechanism (Evan and Littlewood, 
1998). 
 
4.3 LMP-1 may have Induced Cell Cycle Arrest via Upregulation of 14-3-3α and 
Reprimo 
To investigate the candidate genes that involved in LMP-1 induced cell cycle arrest, we 
evaluated the expression level of different cell cycle arrest genes in LMPs expression 
cells. Based on our observations, LMP-1 may induce cell cycle arrest at G2/M phase of 
cell cycle via upregulation of 14-3-3σ and Reprimo expression (Figure 3.7, Figure 3.9 
and Figure 3.11).  
Recently, researches in 14-3-3 proteins have achieved increasing interest in 
many fields of biology. 14-3-3σ protein belongs to a highly conserved acidic protein 
family which has seven isoforms in mammals. Most of the 14-3-3 family members are 
involved in regulating signaling pathway, apoptosis, adhesion, cellular proliferation, 
diferentiation and survival (Mhawech, 2005). Of all the seven isoforms, only 14-3-3σ 
seemed to be involved directly to human cancer (Hermeking, 2003; Hermeking, 2006; 
Robert et al., 2002). 14-3-3σ is a p53 regulated inhibitor of G2/M progression 
(Hermeking et al., 1997; Mhawech, 2005). Ectopic expression of 14-3-3σ protein 
results in G2 arrest via inhibition of cyclin dependent kinase activities in many breast 
cancer cell lines (Laronga et al., 2000).   
 Reprimo, a highly gylcosylated protein and p53 regulated G2/M progression 
regulator, is a candidate gene that is involved in G2/M cell cycle arrest. Ectopic 
expression of p53 protein induced its mRNA expression and subsequently induced 
G2/M cell cycle arrest. In arrested cells, Reprimo is able to inhibit the activity of cdc2 
and nuclear translocation of cyclin B1. Therefore, Reprimo is considered to be another 
p53-induced cell cycle regulator (Ohki et al., 2000). Recently, Reprimo is identified as a 
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potential biomarker for early detection of gastric cancer (Bernal et al., 2008). Besides, 
loss of Reprimo expression due to aberrant methylation was identified in various human 
malignancies and lung cancer (Suzuki et al., 2005; Takahashi et al., 2005).  
In our study, we identified another two downstream targets of p53 which are 14-
3-3σ and Reprimo that may be involved in G2/M arrest in LMP-1 expressing cells. 
However, p53 protein is disabled in 293T cells by E1B and T large antigen; therefore 
we suggest that 14-3-3σ and Reprimo may be upregulated via p53-independent 
pathway. According to Zhang et al. (2004), 14-3-3σ is found to be stimulated by PI3K 
signaling pathway when in response to Insulin-like growth factor 1 (IGF-I). They have 
shown that IGF-I-induced expression of 14-3-3σ consistently even when p53 expression 
was knockdown with siRNA in MCF-7 cells. Therefore, LMP-1 is probably bypass p53 
to induce 14-3-3σ expression in HEK293T cells since LMP-1 involved in many 
signaling pathways. However, the exact mechanism still needs further investigation. On 
the other hand, Reprimo expression in p53-independent manner is not well studied; 
consequently this occurrence may need additional study. Both 14-3-3σ and Reprimo are 
involved in regulation of cdc2 and cyclin B1 pathway (Ohki et al., 2000; Taylor and 
Stark, 2001; Stark and Taylor, 2006). G2/M arrest is important checkpoint to ensure 
normal DNA replication and abnormality of  DNA replication is closely associated with 
genomic instability, tumorigenesis and treatment of tumor (Hoeijmakers, 2001; Khanna 
and Jackson, 2001; Nigg, 2001; O’Connell et al., 2000; Zhou and Elledge, 2000). 
On the other hand, since LMPs are commonly co-expressed and co-localized to 
the same compartment (Longnecker and Kieff, 1990; Lynch et al., 2002; Rovedo and 
Longnecker, 2007), they may probably interact with each other in tumorigenesis. 
However, in our present observation, LMP-2A and 2B were found to have no 
significant changes on LMP-1 induced 14-3-3σ and Reprimo expression as well as 
G2/M arrest. This phenomenon showed that LMP-1 may be a stronger inducer protein 
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that can overcome the effect of LMP-2 or LMP-2A and 2B have no direct interaction 
with LMP-1 in controlling cell cycle progression. This observation still needs further 
investigation to unveil the consequences and functions of LMPs interaction.   
 
4.4 Limitations 
There are several limitations in our current study that need to be addressed and 
improved for future work. Firstly, different transfection efficiency in between the plates 
might affect the expression of the LMPs and thus the interpretation of the results. Cell 
sorter may be useful for making sure that the cells studied contained high level of 
LMPs. Secondly, in order to study LMPs cytostasis, LMP-1 must be expressed in high 
levels. In our study, HEK293T cells were selected due to its SV40 T large antigen that 
can increase the expression level of LMPs by replicating plasmid that contains SV40 
origin. However, not all the cells can achieve high and similar expression level therefore 
a better expression method such as inducible system with doxycycline or tetracyclin 
from stable clone will be able to improve and confirm the results. In addition, more than 
one cell line should be used to increase the persuasive of our study. Lastly, additional 
functional study (or proteins in selected pathways) may be added to our study to reveal 
a better picture of this mechanism.  
Result obtained in this study was only part of the puzzle from LMP-1 induced 
cell cycle arrest therefore it may not sufficient for us to derive conclusive evidences on 
the exact mechanism of LMP-1 induced cell cycle arrest. Therefore, this phenomenon 
may be deserved to further study using different approach such as RNA interference or 
gene knockout techniques. Besides, elucidating the mechanism of LMP-1 induced cell 
cycle arrest in different cell types is important for understanding the growth regulation 
in particular tumor type. Perhaps, we may see a better picture of LMP-1 function in cell 
cycle with investigating the location of LMP-1 in the cell. In that respect, further study 
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can therefore be implemented to study the precise machinery of LMP-1 induced cell 
cycle arrest for understanding this distinct mechanism in EBV associated malignancies.  
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5.1 Conclusion 
In conclusion, LMP-1, 2A and 2B were successfully cloned into pcDNA3.1 
expression vector. Moreover, these LMPs were efficiently expressed in HEK293T cells. 
LMP-1 was able to upregulate the expression of 14-3-3σ and Reprimo. We have shown 
that LMP-1 may induce cell cycle arrest in G2/M phase through the upregulation of 14-
3-3σ and Reprimo. In addition, LMP-2 may not interfere with the function of LMP-1 in 
inducing cell cycle arrest. According to our study, LMP-1 induced the expression of 14-
3-3σ and Reprimo and this mechanism may play some roles in EBV-associated human 
malignancies. Further studies will be required to determine the precise machinery by 
which LMP-1 induces cell cycle arrest for better understanding of this distinct 
mechanism. 
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APPENDIX A: pcDNA3.1 vector 
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APPENDIX B: Sequences of LMP-1, LMP-2A and LMP-2B in EBV B95.8 strain 
Epstein-Barr virus (EBV) genome, strain B95-8 GenBank: V01555.2 
LMP-1 
ATGGAACACGACCTTGAGAGGGGCCCACCGGGCCCGCGACGGCCCCCTCGAGGACCCCCC    60 
CTCTCCTCTTCCCTAGGCCTTGCTCTCCTTCTCCTCCTCTTGGCGCTACTGTTTTGGCTG           120 
TACATCGTTATGAGTGACTGGACTGGAGGAGCCCTCCTTGTCCTCTATTCCTTTGCTCTC       180 
ATGCTTATAATTATAATTTTGATCATCTTTATCTTCAGAAGAGACCTTCTCTGTCCACTT        240 
GGAGCCCTTTGTATACTCCTACTGATGATCACCCTCCTGCTCATCGCTCTCTGGAATTTG       300 
CACGGACAGGCATTGTTCCTTGGAATTGTGCTGTTCATCTTCGGGTGCTTACTTGTCTTA       360 
GGTATCTGGATCTACTTATTGGAGATGCTCTGGCGACTTGGTGCCACCATCTGGCAGCTT     420 
TTGGCCTTCTTCCTAGCCTTCTTCCTAGACCTCATCCTGCTCATTATTGCTCTCTATCTA         480 
CAACAAAACTGGTGGACTCTATTGGTTGATCTCCTTTGGCTCCTCCTGTTTCTGGCGATT      540 
TTAATCTGGATGTATTACCATGGACAACGACACAGTGATGAACACCACCACGATGACTCC  600 
CTCCCGCACCCTCAACAAGCTACCGATGATTCTGGCCATGAATCTGACTCTAACTCCAAC    660 
GAGGGCAGACACCACCTGCTCGTGAGTGGAGCCGGCGACGGACCCCCACTCTGCTCTCAA  720 
AACCTAGGCGCACCTGGAGGTGGTCCTGACAATGGCCCACAGGACCCTGACAACACTGAT  780 
GACAATGGCCCACAGGACCCTGACAACACTGATGACAATGGCCCACATGACCCGCTGCCT   840 
CAGGACCCTGACAACACTGATGACAATGGCCCACAGGACCCTGACAACACTGATGACAAT   900 
GGCCCACATGACCCGCTGCCTCATAGCCCTAGCGACTCTGCTGGAAATGATGGAGGCCCT    960 
CCACAATTGACGGAAGAGGTTGAAAACAAAGGAGGTGACCAGGGCCCGCCTTTGATGACA1020 
GACGGAGGCGGCGGTCATAGTCATGATTCCGGCCATGGCGGCGGTGATCCACACCTTCCT  1080 
ACGCTGCTTTTGGGTTCTTCTGGTTCCGGTGGAGATGATGACGACCCCCACGGCCCAGTT    1140 
CAGCTAAGCTACTATGACTAA                1161 
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LMP-2A 
 
ATGGGGTCCCTAGAAATGGTGCCAATGGGCGCGGGTCCCCCTAGCCCCGGCGGGGATCCG 60 
GATGGGTACGATGGCGGAAACAACTCCCAATATCCATCTGCTTCTGGCTCTTCTGGGAAC 120 
ACCCCCACCCCACCGAACGATGAGGAACGTGAATCTAATGAAGAGCCCCCACCGCCTTAT 180 
GAGGACCCATATTGGGGCAATGGCGACCGTCACTCGGACTATCAACCACTAGGAACCCAA 240 
GATCAAAGTCTGTACTTGGGATTGCAACACGACGGGAATGACGGGCTCCCTCCCCCTCCC 300 
TACTCTCCACGGGATGACTCATCTCAACACATATACGAAGAAGCGGGCAGAGGAAGTATG 360 
AATCCAGTATGCCTGCCTGTAATTGTTGCGCCCTACCTCTTTTGGCTGGCGGCTATTGCC 420 
GCCTCGTGTTTCACGGCCTCAGTTAGTACCGTTGTGACCGCCACCGGCTTGGCCCTCTCA 480 
CTTCTACTCTTGGCAGCAGTGGCCAGCTCATATGCCGCTGCACAAAGGAAACTGCTGACA 540 
CCGGTGACAGTGCTTACTGCGGTTGTCACTTTCTTTGCAATTTGCCTAACATGGAGGATT 600 
GAGGACCCACCTTTTAATTCTCTTCTGTTTGCATTGCTGGCCGCAGCTGGCGGACTACAA 660 
GGCATTTACGTTCTGGTGATGCTTGTGCTCCTGATACTAGCGTACAGAAGGAGATGGCGC 720 
CGTTTGACTGTTTGTGGCGGCATCATGTTTTTGGCATGTGTACTTGTCCTCATCGTCGAC 780 
GCTGTTTTGCAGCTGAGTCCCCTCCTTGGAGCTGTAACTGTGGTTTCCATGACGCTGCTG 840 
CTACTGGCTTTCGTCCTCTGGCTCTCTTCGCCAGGGGGCCTAGGTACTCTTGGTGCAGCC 900 
CTTTTAACATTGGCAGCAGCTCTGGCACTGCTAGCGTCACTGATTTTGGGCACACTTAAC 960 
TTGACTACAATGTTCCTTCTCATGCTCCTATGGACACTTGTGGTTCTCCTGATTTGCTCT 1020 
TCGTGCTCTTCATGTCCACTGAGCAAGATCCTTCTGGCACGACTGTTCCTATATGCTCTC 1080 
GCACTCTTGTTGCTAGCCTCCGCGCTAATCGCTGGTGGCAGTATTTTGCAAACAAACTTC 1140 
AAGAGTTTAAGCAGCACTGAATTTATACCCAATTTGTTCTGCATGTTATTACTGATTGTC 1200 
GCTGGCATACTCTTCATTCTTGCTATCCTGACCGAATGGGGCAGTGGAAATAGAACATAC 1260 
GGTCCAGTTTTTATGTGCCTCGGTGGCCTGCTCACCATGGTAGCCGGCGCTGTGTGGCTG 1320 
ACGGTGATGTCTAACACGCTTTTGTCTGCCTGGATTCTTACAGCAGGATTCCTGATTTTC 1380 
CTCATTGGCTTTGCCCTCTTTGGGGTCATTAGATGCTGCCGCTACTGCTGCTACTACTGC 1440 
CTTACACTGGAAAGTGAGGAGCGCCCACCGACCCCATATCGCAACACTGTATAA          1494 
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LMP-2B 
 
ATGAATCCAGTATGCCTGCCTGTAATTGTTGCGCCCTACCTCTTTTGGCTGGCGGCTATT 60 
GCCGCCTCGTGTTTCACGGCCTCAGTTAGTACCGTTGTGACCGCCACCGGCTTGGCCCTC 120 
TCACTTCTACTCTTGGCAGCAGTGGCCAGCTCATATGCCGCTGCACAAAGGAAACTGCTG 180 
ACACCGGTGACAGTGCTTACTGCGGTTGTCACTTTCTTTGCAATTTGCCTAACATGGAGG 240 
ATTGAGGACCCACCTTTTAATTCTCTTCTGTTTGCATTGCTGGCCGCAGCTGGCGGACTA 300 
CAAGGCATTTACGTTCTGGTGATGCTTGTGCTCCTGATACTAGCGTACAGAAGGAGATGG360 
CGCCGTTTGACTGTTTGTGGCGGCATCATGTTTTTGGCATGTGTACTTGTCCTCATCGTC 420 
GACGCTGTTTTGCAGCTGAGTCCCCTCCTTGGAGCTGTAACTGTGGTTTCCATGACGCTG 480 
CTGCTACTGGCTTTCGTCCTCTGGCTCTCTTCGCCAGGGGGCCTAGGTACTCTTGGTGCA 540 
GCCCTTTTAACATTGGCAGCAGCTCTGGCACTGCTAGCGTCACTGATTTTGGGCACACTT 600 
AACTTGACTACAATGTTCCTTCTCATGCTCCTATGGACACTTGTGGTTCTCCTGATTTGC 660 
TCTTCGTGCTCTTCATGTCCACTGAGCAAGATCCTTCTGGCACGACTGTTCCTATATGCT 720 
CTCGCACTCTTGTTGCTAGCCTCCGCGCTAATCGCTGGTGGCAGTATTTTGCAAACAAAC 780 
TTCAAGAGTTTAAGCAGCACTGAATTTATACCCAATTTGTTCTGCATGTTATTACTGATT 840 
GTCGCTGGCATACTCTTCATTCTTGCTATCCTGACCGAATGGGGCAGTGGAAATAGAACA 900 
TACGGTCCAGTTTTTATGTGCCTCGGTGGCCTGCTCACCATGGTAGCCGGCGCTGTGTGG 960 
CTGACGGTGATGTCTAACACGCTTTTGTCTGCCTGGATTCTTACAGCAGGATTCCTGATT 1020 
TTCCTCATTGGCTTTGCCCTCTTTGGGGTCATTAGATGCTGCCGCTACTGCTGCTACTAC 1080 
TGCCTTACACTGGAAAGTGAGGAGCGCCCACCGACCCCATATCGCAACACTGTATAA  1137 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
